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Abstract 
Obesity and type 2 diabetes (T2D) are associated with reduced metabolic flexibility and 
the development of these conditions are positively associated with dietary saturated fatty 
acids (e.g. palmitic acid) and negatively associated with poly- and monounsaturated fatty 
acids (e.g. ω-3 eicosapentaenoic acid and oleic acid). Furthermore, obesity is strongly 
associated with insulin resistance and T2D, however some extremely obese individuals 
may possess certain characteristics that protect them against developing T2D. Moreover, 
physical activity plays a central role in both prevention and improvement of these 
conditions and we wanted to establish an in vitro model for exercise (electrical pulse 
stimulation) to study these effects. This thesis aimed to explore some aspects of energy 
metabolism, especially lipid storage and turnover and metabolic flexibility in human 
skeletal muscle cells. 
Eicosapentaenoic acid increased metabolic flexibility and lipid accumulation and 
upregulated interleukin-6 (IL-6) mRNA expression in myotubes from lean individuals. 
Palmitic acid had a lower lipid accumulation and upregulated adipose triacylglycerol lipase 
protein expression compared to oleic acid in myotubes. Eicosapentaenoic acid co-
incubation with palmitic and oleic acid eliminated the differences by increasing palmitic 
acid accumulation. Furthermore, myotubes showed a higher palmitic acid oxidation than 
oleic acid oxidation, and palmitic acid upregulated the β-oxidation pathway. Furthermore, 
a reduced insulin response was observed in myotubes isolated from T2D subjects. 
Mitochondrial content and lipid accumulation was higher, while lipolysis was lower in 
extremely obese non-diabetic myotubes compared to cells from extremely obese diabetics. 
Besides, the metabolic flexibility parameters adaptability was higher and substrate-
regulated flexibility tended to be higher in non-diabetics. However, myotubes from 
extremely obese subjects had a higher fatty acid oxidation, but a lower suppression of 
glucose on fatty acid oxidation than the myotubes from lean subjects. After electrical pulse 
stimulation of the myotubes derived from lean, healthy donors, number of lipid droplets 
and IL-6 mRNA expression tended to be higher, while oxidation, mitochondrial content, 
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muscle fiber type I marker expression and insulin sensitivity was higher than in 
unstimulated myotubes.  
The results presented in this thesis, from extremely obese diabetic cells and 
electrical pulse stimulated/fatty acid-treated cells, suggest a favorable role of a higher 
capacity for intramyocellular lipid accumulation and increased metabolic flexibility with 
regards to improved insulin sensitivity and glucose metabolism in human skeletal muscle. 
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Introduction 
 
Obesity 
Lifestyle diseases as obesity and diabetes type 2 (T2D) are rapidly increasing worldwide 
(see Figure 1). In 2008 it was revealed that 40 % of the Norwegian population was 
overweight and that 10 % of these were obese [1]. 
Overweight and obesity is usually defined either by body mass index (BMI), waist 
circumference or waist-hip-ratio (WHR). BMI ≥ 25 kg/m2 is considered overweight and 
BMI ≥ 30 kg/m2 is considered obese, whilst a BMI ≥ 40 kg/m2 is considered morbidly or 
extremely obese [2, 3]. Another method to define obesity is to consider the waist 
circumference or the WHR, which are considered above normal for European 
females/males if higher than 80/94 cm and 0.85/0.90 respectively [4, 5]. The reason for 
using WHR or circumference is that several studies have shown that visceral obesity poses 
a great health risk [6-10]; despite this, BMI is still the most used clinical measure. Some 
obesity scales also considers age, gender and ethnicity, although this is still controversial 
[11]. In most cases, obesity is caused by a combination of inactivity and excessive food 
energy intake (diet), although genetics and stress are factors that also may be involved [12-
15]. The gut microbiota may also influence metabolic processes and should also be 
considered as an environmental factor that could contribute to obesity and its comorbidities 
[16]. 
A person that has accumulated so much fat that it negatively influences their health 
may be considered as overweight or obese [9, 17]. Overweight and obesity are strongly 
associated with insulin resistance and T2D [18, 19], and the majority of individuals with 
T2D are also classified as overweight or obese [2]. This association is complex and 
involves increased fatty acid release from visceral adipose tissue, a raised level of plasma 
free FAs (FFA) and an increased storage of ectopic fat that contributes to insulin resistance 
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in other peripheral tissues [20-22]. Adipose tissue is also an endocrine organ and secretes 
numerous bioactive peptides collectively known as adipokines [23, 24]. Examples include 
peptides such as adiponectin and resistin, hormones like leptin, chemokines such as 
monocyte chemotactic protein 1 and interleukine 8 (IL-8), other pro-inflammatory 
cytokines such as IL-6, IL-1 and tumor necrosis factor -α, and anti-inflammatory peptides 
such as IL-10 [25]. Adipokines are proposed to have a role in the interplay between 
adipose tissue and muscle [26, 27]. Dysfunctional adipose tissue has high triacylglycerol 
(TAG) degradation (lipolysis) that releases more FFA into the circulation. In total, this 
imbalance results in adipose tissue hyperplasia and hypertrophy, which in turn lead to 
inflammation and oxidative stress [28]. Obesity is associated with a chronic low-grade 
inflammation in the adipose tissue [29, 30], perhaps due to an imbalance between 
secretions of pro- and anti-inflammatory adipokines caused by this excessive TAG 
accumulation. In addition, obesity-induced inflammation may therefore be an important 
contributor to the induction of insulin resistance [31] and as part of the negative crosstalk 
between adipose tissue and skeletal muscle; obesity-associated adipokines may promote 
skeletal muscle insulin resistance [32, 33].  
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Type 2 diabetes  
Diabetes increases in concert with obesity (see Figure 1). T2D comprises about 90 % of 
people with diabetes around the world [34] and in addition, undiagnosed T2D is quite 
common [35]. In Norway it is estimated that about 355 000 persons have T2D [36].  
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Figure 1. Incidence of overweight and diabetes in adults worldwide over time and predictions of the time to 
come [2, 37, 38] . 
 
T2D is a chronic metabolic disorder characterized by elevated blood glucose values 
(hyperglycemia) and insulin resistance and/or deficiency. T2D is diagnosed by fasting 
blood ≥7 mmol/l for fasting blood glucose test and/or ≥11.1 mmol/l for a two hours oral 
glucose tolerance test (OGTT) [39]. In addition, glycated hemoglobin levels in blood 
(HbA1c ≥ 6.5 %) may also be determined [40, 41].  The probability of having an HbA1c ≥ 
6.5 % among cases of T2D based on OGTT criteria varies dramatically across ethnicities 
[42]. This indicates that T2D definitions should be adjusted for ethnicity. Furthermore, 
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homeostatic model assessment (HOMA) is a method used to quantify insulin resistance 
and β-cell function with insulin and glucose fasting values and this and hyperinsulinemic-
euglycemic clamp may also be used to measure insulin resistance [43].  
Development of T2D is believed to be caused by a combination of lifestyle factors such 
as physical inactivity, diet, stress, smoking, obesity and alcohol consumption. In addition, 
genetics, age, ethnicity, gender and some medications may predispose people for diabetes 
[44-46]. Treatments against obesity and T2D are mainly lifestyle intervention (physical 
activity and diet), but anti-obesity drugs and weight loss surgery are possibilities and in 
most T2D cases it is necessary to use drugs to normalize blood glucose levels [47].  
As of year 2011, 36 diabetes-associated genes have been found that may contribute to 
the risk of development of T2D [48]. On a cellular level T2D is caused by insulin 
resistance in liver, adipose tissue and muscle, increased lipolysis from adipose tissue, 
increased glucose production in liver and a reduced insulin secretion from β-cells in the 
pancreas [49]. Insulin stimulates glucose utilization and storage of carbohydrates 
(glycogen), lipids and proteins, while inhibiting their degradation and release into the 
circulation. Further, insulin stimulates the uptake of glucose, amino acids and fatty acids 
into cells [50]. Insulin resistance is the inability of cells to respond sufficiently to normal 
levels of insulin.  
Increased fatty acid release from adipose tissue and a raised level of FFA in blood in 
overweight persons is proposed to contribute to insulin resistance in other peripheral 
tissues [51-53]. Insulin resistance and T2D are strongly associated with overweight and 
obesity. Obesity is similarly characterized by reduced glucose uptake in adipose tissue [54], 
nevertheless fat tissue merely contributes to a small part of the total body glucose uptake 
and this alone cannot be the full explanation to the connection between obesity and insulin 
resistance. Moreover, induction of insulin resistance may also be initiated by obesity-
induced inflammation and its corresponding cytokines [31]. There are still much that are 
not fully understood in the relationship between obesity and development of insulin 
resistance. 
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Metabolic syndrome 
T2D increases the risk of cardiovascular diseases (CVD), microvascular complications – 
and even increases mortality [9, 45, 47]. In addition, overweight and obesity also increases 
the mortality and CVD rates, in addition to diabetes, musculoskeletal disorders, sleep 
apnea as well as some cancers [13]. 
Metabolic syndrome is a combination of disorders that increase the risk of 
developing CVD. Obesity or central obesity and insulin resistance or T2D are parts of the 
definition of metabolic syndrome. To diagnose metabolic syndrome the patient must have 
three conditions of the following: elevated waist circumference with regards to ethnic 
origin, dyslipidemia with raised triacylglycerol levels or specific treatment for this lipid 
abnormality, reduced high density lipoprotein (HDL)-cholesterol or specific treatment for 
this lipid abnormality, raised blood pressure or treatment of previously diagnosed 
hypertension or raised fasting plasma glucose or treatment of diagnosed T2D [55]. Causes 
discussed for developing metabolic syndrome are obesity (especially abdominal) and/or 
insulin resistance in addition to physical inactivity, age, hormonal imbalance or genetic 
abnormalities [56]. A study in 2002 estimated that approximately 22 % of American adults 
have the metabolic syndrome [57], indicating that metabolic syndrome is a quite common 
condition. 
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Dietary fat 
Dietary fat is associated with development of obesity, insulin resistance and T2D. Intake of 
saturated fatty acids (SFAs) is positively correlated, while mono- and especially 
polyunsaturated fatty acids (MUFAs and PUFAs, essential fatty acids) have shown 
beneficial effects [58-60]. In a study performed in rats, a diet rich in SFAs caused insulin 
resistance, whereas a diet rich in ω-6 PUFAs resulted in increased insulin sensitivity [59, 
61]. However, replacement of the ω-6 fatty acid (FA) linoleic acid (LA) with ω-3 FAs 
prevented the development of insulin resistance in high-fat fed rats [62]. Haugaard et al 
showed that changes in HOMA-IR were inversely correlated to changes in membrane 
concentrations of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and total ω-3 
FAs, as well as the ratio of ω-3/ ω-6 PUFA in human skeletal muscle [63]. One meta study 
concludes that intake of ω-3 PUFAs might be weakly positively associated with the T2D 
risk [64], and two other meta studies did not find any effect of ω-3 FAs on development of 
T2D or insulin sensitivity [65, 66]. A third meta study reveals an ethnicity difference in the 
response [67]. However, a different meta study found that diets higher in ω-3 long chain 
PUFA may reduce cardiovascular risk in diabetes [68]. Thus, the mechanism by which 
UFAs (unsaturated FAs)/PUFAs exert positive effects on insulin sensitivity are yet unclear 
[69, 70]. Besides, ω-3 may not have an effect on body weight [71-73], however ω-3/UFA 
intake is reported to decrease inflammation in humans [74, 75]. An explanation for this 
may be that PUFAs are precursors for leukotrienes and prostaglandines that act pro-
inflammatory and lipoksines and resolvines that act anti-inflammatory, in addition 
docosanoides [76, 77] and ω-3, as EPA, is precursor for the anti-inflammatory substances 
[78]. In addition, the beneficial effects of PUFAs might be explained in their role in the 
cellular membranes or acylation of proteins that alter membrane plasticity or protein 
function [79]. 
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Energy metabolism in skeletal muscle 
Many organs in the body might be involved in development of obesity and T2D, but 
skeletal muscle is one of the organs where insulin resistance are most prominent. Skeletal 
muscle constitutes about 40 % of human body mass in non-obese individuals and has been 
reported to account for 75-80 % of the body’s insulin-stimulated glucose uptake [49, 80]. 
Skeletal muscle also stores fat, as TAG in lipid droplets (LDs) and both storage and/or 
intermediates in FA metabolism (LCFA-CoAs (long-chain FA-CoAs), diacylglycerol 
(DAG), ceramides etc.) has been shown to be involved in regulation of insulin sensitivity 
[81-84]. Fat is also oxidized in the mitochondria to generate energy and another theory for 
impaired glucose metabolism is apparent mitochondrial dysfunction [85]. Furthermore, 
skeletal muscle metabolism depends on fiber type, flexibility, fitness, the involvement of 
important nuclear receptors and its role as an endocrine organ. In this thesis energy 
metabolism was examined in human myotubes. 
 
Glucose uptake and glucose transporters 
Glucose is a fundamental energy source for all eukaryotic cells and the brain uses 80 % of 
the dietary glucose ingested. In skeletal muscle cells, glucose may be oxidized in 
mitochondria for energy (ATP) production, stored as glycogen or contribute as a precursor 
for lipid synthesis.   
Muscle cells take up glucose in the basal, insulin-stimulated or contraction state. 
Insulin-stimulated glucose uptake is initiated by insulin binding to the insulin receptor (see 
Figure 2). Rab8A and Rab13 are proposed as responsible Rabs that regulate glucose 
transporter 4 (GLUT4)-translocation in muscle cells [86]. In addition, TBC1D1 is another 
Rab GTPase-activating protein that also might be involved in regulation of glucose 
transport [87, 88], however this mechanism is not clear.  
Muscle insulin resistance is most likely due to dysfunctional GLUT4 translocation [89, 
90]. However, GLUT4 overexpression in skeletal muscle was shown to increase insulin- 
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and contraction-stimulated glucose transport and glucose metabolism [91]. Human 
myotubes express GLUT1, GLUT3 and GLUT4 (preliminary data from our lab). The 
physiological role of GLUT3 is still unclear [92]. GLUT1, which has been proposed to be 
responsible for basal glucose uptake in human muscle cells [93-95], was reduced in cells 
from T2D individuals, while mRNA levels were similar [95]. Nevertheless, GLUT4 levels 
in skeletal muscle are largely regulated at the level of transcription and this might as well 
be the case for GLUT1 as well [96]. 
The dysfunctional insulin-stimulated GLUT4 translocation seen in diabetic muscle 
might be a result of abnormal FA accumulation or disruptions in the lipid storage dynamics 
and consequent interaction with protein kinase C (PKC) or ceramide on insulin signaling 
[83, 97-101]. Ceramides may inhibit serine/threonine phosphorylation of Akt/PKB (protein 
kinase B) [102-104] and muscle ceramides are observed elevated in obese [105], insulin 
resistant [106] or obese insulin resistant [107] subjects. SFAs (such as palmitic acid, PA) 
may induce insulin resistance in muscle, most likely via formation of ceramides [108] and 
phosphorylation of Akt substrate of 160 kDa (AS160) is observed reduced in myotubes 
after PA treatment [109] (see Figure 2).  
PKC may disturb the GLUT4 translocation by serine phosphorylation of insulin 
receptor substrate 1 (IRS-1) [101, 110]. DAG may activate PKCε and PKCθ (see Figure 2). 
DAGs are intracellular second messengers and an intermediate in TAG synthesis and 
degradation (lipolysis) [101] and has been seen to be positively associated [111, 112] with 
obesity/insulin resistance in human muscle. In contrast, there are also studies showing 
inverse association with insulin resistance after high-fat diets in rats [113]. Similar DAG 
content in obese/insulin resistant subjects [106, 114] or increased DAG content in athletes 
[107] has also been found. The subcellular location, saturation and different stereoisomers 
of DAG may play a role and might be the reason for these conflicting results. For instance, 
Bergman et al showed that membrane DAG was associated with PKCε activation and 
negatively associated with insulin sensitivity and more abundant in diabetics, while 
cytoplasmic DAG was not. Furthermore, disaturated DAG species were negatively 
correlated with insulin sensitivity [111].  
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Figure 2. Insulin-stimulated glucose uptake. Insulin-stimulated glucose uptake is initiated by insulin (purple 
circle) binding to the insulin receptor (IR) at the plasma membrane followed by activation of insulin receptor 
substrate (IRS) and an insulin-signaling cascade involving the activation by phosphorylation of Akt (protein 
kinase B (PKB)) [50, 115].  Akt phosphorylates Akt substrate of 160 kDa (AS160 or TBC1D4), which is 
identified as a regulator of the insulin-stimulated glucose transporter 4 (GLUT4) trafficking and glucose 
uptake in muscle cells [116-118]. AS160 has a GTPase-activating protein domain that is thought to preserve 
Rab’s inactive GDP form and phosphorylation of AS160 will result in an active Rab-GTP form which 
facilitates glucose transporters (GLUT4)-containing vesicle exocytosis and consequently glucose (Glc) 
uptake mediated by GLUT4 transporters [119-121]. Saturated fatty acids (SFA) may result in ceramide 
influence on Akt phosphorylation and diacylglycerol (DAG) may activate protein kinase C (PKC) that may 
inhibit IRS. The star represents a phosphorylation.  
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Fatty acid uptake, transporters and binding proteins 
FAs are important energy source, and for instance heart and skeletal muscle prefer FAs as 
an energy source. Once inside a cell, FAs will be activated to FA-CoA and may be 
esterified to TAG for storage (LDs) or incorporated into phospholipids for use in cellular 
membranes. They can also be metabolized to lipid second messengers, such as eicosanoids, 
oxidized in the mitochondria for energy (ATP) production or alter gene expression. FAs 
may be supplied by diet or synthesized from glucose (de novo lipogenesis). FAs are 
transported to muscle as free FAs bound to albumin, or derived from TAG in chylomicrons 
or very low density lipoproteins in the plasma, where the FAs are liberated by (LPL) 
lipoprotein lipase before cellular uptake [122]. 
FA uptake can occur through passive diffusion or via protein-mediated mechanisms 
using transporters such as FA translocase (CD36/FAT), FA binding protein (FABPpm) and 
FA transport proteins (FATP1-6) [123, 124]. FATP1 and FATP4 are the most abundant 
FATP expressed in muscle [125]. Insulin has also been observed to induce translocation of 
intracellular stored CD36 and FATP1 to the plasma membrane in muscle [126-129], while 
FATP1-KO mice were protected against diet-induced insulin resistance in skeletal muscle 
[128, 130]. FABPpm translocation, however, is not induced by insulin, although 
overexpression modestly increased FA uptake. In addition, FABPpm and CD36 are found 
to coimmunoprecipitate, indicating direct interaction and a potential collaboration [131]. 
Muscle contraction may also facilitate FA uptake through both FABPpm and CD36 
translocation [123, 132] (see Figure 3). However, contraction-induced CD36 trafficking 
and FA uptake is proposed to be AMP-activated protein kinase (AMPK) independent 
[132]. In cultured human myotubes, FATP1 is found in the cytosol, while CD36 is overtly 
present in the plasma membrane [133]. An increase in FA uptake is hence not associated 
with an increase of total expression of transporters, but rather an increase in transporters at 
the plasma membrane [132, 134]. Once the FAs enter the cell, FABPc transports them to 
their destination or they may react with acyl-CoA synthetase (ACSL) and become FA-CoA 
and is then transported by acyl-CoA binding protein (ACBP) [135].  
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Figure 3. Fatty acid cell uptake. Fatty acid (FA, green oval circle with blue tale) may be taken up by the cell 
via passive diffusion or via FA translocase (CD36/FAT), FA binding protein (FABPpm) and FA transport 
proteins (FATP1-6). FATP1 and CD36 translocate to plasma membrane in response to insulin or and CD36 
and FABPpm translocate in response to contraction. Once the FAs enter the cell they are transported to their 
destination by FABPc or they may react with acyl-CoA synthetase (ACSL) and become (LC)FA-CoA (long-
chain FA – CoA) which is then transported by acyl-CoA binding protein (ACBP). Orange circle is a CoA 
molecule. 
 
Malfunctioning of recycling of FA transporters may lead to increased intracellular 
TAG accumulation and cellular insulin resistance. Earlier studies have shown a higher FA 
uptake in obese and/or diabetic muscle [136-138]. One in vivo study found that FABPc 
was not regulated by insulin in muscle [127], whereas other studies have found a 
correlation between FABPc and weight loss in human muscle biopsies [139]. Beside this, 
the concentration of ACBP was higher in muscles from insulin-resistant obese Zucker rats 
than in muscles from lean Zucker rats and it is proposed that the concentration of acyl-CoA 
(FA-CoA) in the cytosol might have an influence on insulin resistance [140]. Bell et al 
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found a higher protein expression of CD36 in myotubes from morbidly obese compared to 
lean subjects [138]. There has also been observed that CD36 mRNA expression in muscle 
biopsies was reduced after a two-month bed rest (inactivity) in humans [141]. Several 
studies have concluded that CD36 in relation to obesity and T2D were dependent on 
translocation to the plasma membrane [134, 142, 143]. In accordance to this, a study in 
muscles from obese Zucker rats proposed that these rats were insulin resistant with respect 
to CD36 translocation and FA uptake, whilst FABPpm was unchanged [144]. Furthermore, 
diabetic Zucker rats fed a high-fat diet had an increased total and sarcolemmal CD36 
protein expression, but with exercise, a reduction was seen [145]. Bell et al. wanted to 
mimic the obese situation by overexpression of CD36 in myotubes and although this 
increased FA uptake, it did not impair insulin signal transduction [138]. Furthermore, 
GLUT4 and CD36 seem to have quite similar regulation, at it remains to be elucidated 
[146]. Altogether, this indicates a complex regulation of FA uptake and CD36 function in 
skeletal muscle dependent on status. The majority of the FAs taken up by muscle (up to 90 
% in soleus muscle) are either oxidized or stored as TAG, while the rest ends up in 
phospholipids, monoacylglycerol (MAG), DAG and cholestryl ester pools [147].  
 
Lipid storage in cells - lipid droplets (LDs) and PLINs 
FAs entering the cell are mainly partitioned between mitochondrial oxidation and TAG 
synthesis and LD storage [123]. In skeletal muscle about 50 - 60 % of the FAs taken up are 
stored as TAG in LDs [148], referred to as intramyocellular lipid (IMCL) or 
intramyocellular triacylglycerol (IMTG). LDs are dynamic organelles that interact with 
almost all other organelles in the cell, and are involved in signaling and lipid trafficking, 
while they also contain a fuel source for mitochondria. LDs contain mainly TAG, but also 
DAG, cholesteryl ester and free cholesterol, surrounded by a monolayer of phospholipids 
and proteins [149, 150].  
LDs are coated by LD-binding proteins (PLINs/perilipins) that regulate LD biogenesis 
[151-153], and in human skeletal muscle all five PLINs are present. In cultured human 
myotubes PLIN2 and 3 were found to be dominant, whereas expression of PLIN4 and 
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PLIN1 were very low and no expression of PLIN5 was found [154]. PLIN2 covers 61 % of 
IMCL in human muscle biopsies [155] and is anticipated to protect the LD against lipolysis 
[156]. In addition, PLIN2 mRNA expression is positively associated with FA exposure in 
human skeletal muscle cell [154] or high-fat diet in mice [157], however oleic acid (OA) is 
shown to be a more potent inducer than PA in C2C12 cells [158]. PLIN3 suppression in 
HeLa cells resulted in a blocked LD maturation and decreased incorporation of TAG into 
LDs and PLIN3 is thought to be involved in LD synthesis [159]. PLIN3 increase with OA 
exposure, but not EPA exposure, in human skeletal muscle cells [154]. 
Several studies have shown a positive relation between LD or IMCL accumulation 
and obesity/T2D in muscle [145, 160-162]. Surprisingly, it has been shown that also 
subjects who exercise regularly (athletes) have elevated IMTG levels, despite a higher 
insulin sensitivity and higher oxidative capacity, compared to untrained persons [107, 162, 
163], even when compared to T2D muscle fibers [163]. This is referred to as the “athlete’s 
paradox”. In addition, IMTG level has been found to be similar in muscle from T2D and 
lean individuals [164, 165] and increasing IMTG did not necessarily increased insulin 
resistance [100, 166]. Altogether, more recently, researchers believe that IMTG/IMCL 
accumulation within skeletal muscle per se may not be directly linked to insulin resistance 
[167], but rather a high IMTG turnover protects the cells and prevents accumulation of 
lipotoxic intermediates as PKC and ceramides [83, 99, 168-170]. 
To elaborate this theory, regulation of LD biogenesis and turnover in skeletal 
muscle needs to be further elucidated and in this context; the roles of the PLINs are 
important. PLIN2 overexpression in vitro in C2C12 cells and in vivo in rats increased 
IMTG and was paralleled with improved insulin sensitivity as a result of rescued PA or 
high fat diet induced impairment of insulin stimulated glucose uptake. PLIN2 knockdown 
in C2C12 myotubes, however, decreased LD formation and TAG storage [157]. In 
addition, a lower PLIN2 mRNA expression has been seen in muscle biopsies from insulin 
resistant compared to insulin sensitive subjects [106]. In contrast to this, some human 
studies could not see a correlation between PLIN expressions and insulin sensitivity [154, 
171] and results from muscle biopsies has also shown a similar PLIN2 protein expression 
between obese non-diabetics and obese diabetics or obese and lean subjects [172, 173]. 
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Furthermore, an increased PLIN2 protein content is observed with weight loss in non-
diabetics [171, 173]. Despite all this, PLIN2-KO mice have normal body weight and fat 
mass [174]. PLIN3 protein expression has been found to be lower or similar in muscle 
biopsies of obese compared to non-obese individuals [145, 171] and reduction of PLIN3 in 
liver increased glucose uptake in skeletal muscle of mice [175].  
In adipocytes, PLIN1 is highly expressed and is phosphorylated by the cAMP-
dependent kinase protein kinase A (PKA) to initiate lipolysis via interaction with hormone 
sensitive lipase (HSL) [176-178] (see Figure 4). Although this is not yet thoroughly 
examined in PLINs from skeletal muscle, researchers speculate that PLIN2 may have some 
of the same properties [157, 179].  Accordingly, phosphorylations and translocations of 
PLIN2 might be important [177, 180]. In addition, so far it has been discovered 4 isoforms 
of PLIN1 and this might as well be the case for the others PLINs [181].  
 
Lipid droplet turnover - esterification and lipolysis 
LDs consist mainly of TAG. The FAs taken up by the cell destined for storage react with 
ACSL and become FA-CoA that may be converted into MAG via monoacyglycerol 
acyltransferase (MGAT) to form DAG. DAG is converted to TAG catalyzed by 
diacylglycerol acyltransferase (DGAT) 1 or 2 [182] (See Figure 6). DGAT1 
overexpression in rats has resulted in a higher level of IMCL, DAG content and glucose 
uptake in skeletal muscle. In addition, rats on high-fat diets overexpressing DGAT1 
showed increased PLIN2, PLIN5, adipose triacylglycerol lipase (ATGL), CGI-58 protein 
expression and had larger and more LDs in their muscle [113]. However, Bergman et al 
found that DGAT1 protein expression was similar in muscle biopsies in athlete, obese and 
obese T2D individuals [111]. In myotubes, DGAT2 mRNA expression was found to be 
lower in obese T2D compared to obese [183]. DGAT1 protein expression has been seen to 
be lower in muscle biopsies from obese compared to non-obese individuals, while DGAT2 
and glycerol phosphate acyltransferase 1 protein as well as DGAT and glycerol phosphate 
acyltransferase activity was not different between the groups [145]. This indicates a 
discrepancy between expression and activity due to modification of these enzymes.  
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Degradation of TAG by lipolysis after stimuli for energy demand is driven by the 
lipases ATGL, HSL and monoacylglycerol lipase (MGL). ATGL is expressed in human 
skeletal muscle [184-188] and is proposed to be the major lipase that initiates lipolysis by 
hydrolyzing TAG to DAG [189]. HSL is also expressed in human skeletal muscle [190, 
191] and has the function to hydrolyze DAG to MAG and, to a smaller extent, TAG to 
DAG [192]. In the end, MGL hydrolyzes MAG to glycerol (see Figure 4 and 6). β-
adrenergic stimuli with catecholamines may increase lipolysis by phosphorylation of 
PLIN1 and HSL via PKA in adipose tissue [176, 193-195], and by phosphorylation of HSL 
in skeletal muscle [196-198]. In adipose tissue, HSL needs to be phosphorylated by PKA at 
least at two sites before translocation to the LD membrane [195], and in Drosophila it is 
suggested that PLINs regulate this HSL translocation [195]. AMPK activation is also 
reported to phosphorylate HSL and even override β-adrenergic stimuli on HSL activity 
[199, 200]. ATGL has a cofactor comparative gene identification-58 (CGI-58) [201] and 
overexpression increases TAG hydrolase activity by 2-fold in skeletal muscle cells [184]. 
One theory is that ATGL and CGI-58 is bound in cytoplasma, while ATGL is liberated 
when bound to the LD activating lipolysis [202-204]. In addition a ATGL inhibitor 
G(0)/G(1) switch gene 2 (G0S2) is identified in adipose tissue [205], non-competitive of 
CGI-58 [204], but not yet identified in skeletal muscle. Nevertheless, little is known about 
this regulation involving PLINs, phosphorylations, cofactors and translocations of lipases 
in skeletal muscle. A model of lipolysis is presented in Figure 4 [206]. 
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Figure 4. Model of lipolysis. β-adrenergic receptors (β-AR) are activated by the binding of catecholamines 
(blue circle). This stimulation results in activation of adenylyl cyclase (AC) that subsequently activates 
protein kinase A (PKA), which phosphorylates hormone-sensitive lipase (HSL) and PLIN/perilipin. 
Phosphorylation of PLIN facilitates both interactions between phosphorylated HSL and its lipid substrate, 
and releases comparative gene identification-58 (CGI-58) from the lipid droplet (LD). Then, CGI-58 
translocates to the cytosol where it interacts with adipose triacylglycerol lipase (ATGL). The translocation of 
ATGL to the LD allows for the hydrolysis of triacylglycerol (TAG) to diacylglycerol (DAG). Phosphorylated 
HSL translocates to the LD to hydrolyze DAG. Monoacylglycerol lipase (MGL) finally hydrolyzes 
monoacylglycerol (MAG) to glycerol (red line) and FA (green oval circle with blue tale). G(0)/G(1) switch 
gene 2 (G0S2) might contribute as an inhibitor of ATGL. AMPK activation is also reported to phosphorylate 
HSL. The star represents a phosphorylation event. An average human cultured muscle fiber has about 30-100 
LDs per nuclei. 
 
Studies showing TAG accumulation in subjects suffering from neutral lipid storage 
disease, where ATGL function is impaired, clearly demonstrate an important role of ATGL 
in skeletal muscle lipid metabolism [207]. ATGL-KO mice had a lower lipolysis, higher 
accumulation of TAG and a higher glucose uptake in skeletal muscle [208], while ATGL-
deficient animals showed improved glucose tolerance and enhanced insulin sensitivity 
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despite TAG accumulation in various tissues [209]. On the other hand, HSL-deficient mice 
had increased DAG levels in adipose tissue, cardiac and skeletal muscle [210]. HSL null 
mice have shown to be insulin resistant [195] or showed signs of impaired insulin 
sensitivity [211]. Supply of glucose may play a role in mediating lipase activity in skeletal 
muscle [212] as well as β-adrenergic induced lipolysis was blunted in muscle of obese 
individuals [213]. In muscle biopsies from obese/insulin resistant subjects, Jocken et al 
observed a lower lipolysis and a lower HSL protein expression and phosphorylation 
compared to lean healthy subjects [198, 214, 215]. In addition, they observed a higher 
ATGL protein level in obese subjects compared to lean [215] and a lower level in non-
obese diabetics and higher in obese diabetics compared to healthy lean controls [214]. This 
may indicate that the ratio between these lipases is important and that the obesity and 
diabetic effects are different. These results are in accordance with that several theories 
regarding development of insulin resistance/T2D in muscle involve a dysregulation of LD 
turnover rather than the LD accumulation itself [83, 99, 168-170]. 
 
 
Mitochondrial oxidation and function 
Once the FAs are stored in LDs as TAG, they can, on stimuli for energy demand, 
undergo lipolysis and become available substrates for oxidation. To get there, ACSL first 
catalyzes the reaction of FA to FA-CoA esters, which are substrate for carnitine 
palmitoyltransferase 1 (CPT1) on the outer mitochondrial membrane [216] and are 
transported over the mitochondrial membrane (see Figure 5). FAs may also enter the cell 
and be transported directly to the mitochondria, without entering LDs first. Incomplete 
oxidation occurs when β-oxidation rates are higher than TCA-cycle or ETC rates [217, 
218]. Carnitine O-acetyltransferase (CrAT) is a mitochondrial matrix enzyme that plays a 
key role in the synthesis and efflux of short-chain carnitine conjugates, such as acetyl-
carnitine [219].   
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Figure 5. Mitochondria function. To cross the inner mitochondrial membrane, FA-CoA (green oval circle 
with blue tale) react with carnitine palmitoyltransferase 1 (CPT1) and carnitine-FA is transported via 
carnitine/acylcarnitine translocase (CACT) [220], and the acyl-CoA form is regenerated by CPT2 on the 
inner mitochondrial membrane [219]. Once inside the mitochondria, FA-CoA goes through β-oxidation with 
several chain-shortening reactions that are catalyzed by mitochondrial trifunctional protein  [221], which 
results in acetyl-CoA that enters the tricarboxylic acid cycle (TCA, Kreb’s). TCA cycle reduces NAD+ to 
NADH and produces carbon dioxide (CO2).  The NADH generated is fed into the oxidative phosphorylation 
pathway. The electron transport chain (ETC) is the site of oxidative phosphorylation in eukaryotes. ETC 
couples electron transfer between an electron donor (NADH) and an electron acceptor (O2) with the transfer 
of protons across a membrane with the help of several components, as complex I-V and cytochrome c (Cyc) 
that passes electrons from complex III to IV, and ATP synthase. The end products from these processes are 
water and energy in the form of ATP [222].  
 
Once glucose enters the cell, it may undergo glycolysis, which results in pyruvate that 
enters the mitochondria via different transporters. The pyruvate dehydrogenase (PDH) 
complex converts pyruvate to acetyl-CoA that can enter the TCA cycle and thereby 
competing with FAs as substrate for energy production [219] (see Figure 5 and 6). 
Pyruvate dehydrogenase kinase isozyme 4 (PDK4) is an inhibitor of the PDH complex and 
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is therefore an important factor in switching oxidation towards FAs [223]. Furthermore, 
citrate, an intermediate in TCA cycle may escape the mitochondria and be converted to 
acetyl-CoA in cytosol. Lipogenesis is the process by which acetyl-CoA is converted to fats.  
First, acetyl-CoA is converted to malonyl-CoA by acetyl-CoA carboxylase (ACC) [224] 
and ACC2 is the dominant isoform expressed in skeletal muscle [225]. Thereafter, 
malonyl-CoA can be used for FA synthesis by the action of FA synthase (FASN), and FAs 
can be further elongated and desaturated by elongases, stearoyl-CoA desaturases (SCDs) 
and FA desaturases (FADSs) (see Figure 6) [224]. Insulin stimulates this pathway by 
increasing the pool of malonyl-CoA via PDH and ACC dephosphorylation [226] and 
LCFA-CoAs might directly affect glucose utilization by altering the activity of glycolytic 
enzymes and is elevated in obesity and extreme obesity [227]. 
Dietary short-chain and UFAs are more rapidly oxidized than dietary long-chain and 
SFA in whole-body of healthy subjects [228]. In contrast to this, in human skeletal muscle 
cells, it has been reported that palmitic acid (PA, SFA) oxidation was greater than oleic 
acid (OA, MUFA) oxidation. Human myotubes incubated with PA and OA for 16 h 
showed higher incomplete and complete oxidation of FAs when exposed to PA compared 
to OA [133]. In total, saturation of FAs and hence diet may affect mitochondrial oxidation, 
which is a central component when discussing obesity. The current consensus is that 
obesity and T2D are associated with reductions in oxidation in skeletal muscle [227, 229-
232]. In addition, studies performed on human skeletal muscle cells are few, and those 
from obese T2D individuals (BMI ≥ 30 kg/m2) have shown similar or reduced ability to 
oxidize FAs compared to obese/lean individuals [183, 233-236]. There are also studies in 
extremely obese individuals (BMI ≥ 40 kg/m2) were they found that the extremely obese 
subjects had a reduced complete FA oxidation related to lean subjects [138, 237, 238]. 
However, increasing FA oxidation does not prevent insulin resistance [239], and 
decreasing FA oxidation has even shown improved insulin sensitivity in diet-induced 
obese mice [240]. There are also reports on unaltered and/or increased FA oxidation in 
human skeletal muscle of obese or insulin resistant individuals [136, 241-245]. An 
increased ability to oxidize FAs has been seen in isolated mitochondria from muscle of 
obese T2D individuals [246]. Furthermore, high-fat feeding has been associated with 
increased incomplete oxidation [247], mitochondrial DNA copy number and citrate 
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synthase [248, 249] in rat muscle. This is in line with the observed increased citrate 
synthase activity in human muscle tissue of obese compared to lean [142]. Thus, the aspect 
of FA oxidation in relation to insulin resistance and obesity remains controversial.  
Mitochondrial deficiency may also be a contributing factor towards development of 
T2D [164, 165, 250, 251]. The above mentioned reduced oxidation in obese/T2D muscle 
has been attributed to impaired mitochondrial capacity [250, 252, 253] or lower 
mitochondrial content [231].  Furthermore, several studies conclude that the observed 
reduced mitochondrial function in T2D is due to, and secondary to, a lower mitochondrial 
content in muscle [250, 254-256]. A reduced mitochondrial content has been observed in 
obese muscle [231], extremely obese myotubes [238], as well as in insulin resistant 
skeletal muscle [85, 250, 252, 257-261]. Insulin has emerged as a regulator of 
mitochondrial biogenesis [262, 263], and it might be that a blunted insulin signaling 
contributes to a decreased mitochondrial content rather than reverse [264]. At the same 
time, mitochondrial content has in different studies been shown to correlate both 
negatively and positively with FA oxidation in myotubes [236, 265]. So far, it is not clear 
whether mitochondrial dysfunction represents a cause or a consequence of T2D or obese 
phenotype.   
Together with reduced FA oxidation, a higher lipid uptake is observed in extremely 
obese myotubes [138]. However, isolated mitochondria from obese individuals do not have 
lower CD36 protein level or PA oxidation than lean individuals; nevertheless in lean and 
obese subjects together, these parameters correlated, suggesting a regulatory role for CD36 
at the level of the mitochondria [241, 266]. There is also a study in which colocalization 
between FATP1 and CPT1 was found in L6 myotubes and an interaction is proposed [267]. 
Although another study by Garcia-Martinez [133] in human myotubes found no difference 
in incomplete oxidation and reduced complete oxidation when overexpressing FATP1 and 
CD36. They propose a closer relationship to lipid storage, but this needs to be further 
elucidated. Figure 6 reveals the full picture of energy metabolism in skeletal muscle. 
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Figure 6. Energy metabolism in skeletal muscle. Glucose is transported into cells through transporters and 
either stored as glycogen or utilized through glycolysis to yield pyruvate. Uptake of fatty acids (FAs) is 
facilitated by different transport proteins (FAT/CD36, FATP, FABPpm). Intracellular FAs are bound to 
cytosolic FA binding proteins (FABPc) and activated by acyl-CoA synthetase (ACSL). FA-CoAs can be 
incorporated into complex lipids as diacylglycerol (DAG), triacylglycerol (TAG) and phospholipids (PL), 
and assembled in lipid droplets (LDs) for storage via the action of diacylglycerol acyltransferase (DGAT) 
and monoacylglycerol acyltransferase (MGAT). TAG and DAG are hydrolyzed by adipose triglyceride lipase 
(ATGL) and hormone-sensitive lipase (HSL). FA-CoAs are transported into mitochondria via carnitine 
palmitoyltransferase (CPT) 1 and 2, and thereafter metabolized through β-oxidation, yielding acetyl-CoA, 
which enters the TCA-cycle. Pyruvate derived from glucose may also enter the mitochondria and the TCA- 
cycle through the action of the pyruvate dehydrogenase (PDH) complex. Citrate that escapes TCA-cycle is 
converted to acetyl-CoA in cytosol, and thereafter to malonyl-CoA by acetyl-CoA carboxylase 2 (ACC2). 
Malonyl-CoA decarboxylase (MCD) catalyzes the reverse reaction. Malonyl-CoA can be used for FA 
synthesis by the action of FA synthase (FASN), which can be further elongated and desaturated by elongases 
and stearoyl-CoA desaturases (SCDs), respectively. Malonyl-CoA inhibits CPT1, acetyl-CoA inhibits the 
PDH complex and cytosolic citrate inhibits glycolytic enzymes. Figure adapted and modified from [268]. 
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Fiber types 
Skeletal muscle consists of different muscle fiber types; fiber type I, IIa, IIx and IIb. Type I 
are slow twitch fibers, while type II are fast twitch fibers. In addition, type I are more 
oxidative and have more mitochondria, while type II are more glycolytic. Type I are more 
suited for endurance training, while type II for strength training. Type II fibers have mainly 
three subtypes, a, x and b, where IIb is the fastest fiber and has fewest mitochondria/lowest 
oxidative capacity. Type I, IIa, IIx and IIb are characterized by myosin heavy chain 
proteins (MYH) encoded by the genes MYH7, MYH2, MYH1, MYH4 respectively. 
Human skeletal muscle contains fiber type I and IIa, while to a smaller extent also type IIx 
[269, 270] and different muscles have different composition of the fiber types [271].   
The gene expression of genes involved in lipid storage (IMCL, PLIN2, PLIN5) and 
lipid turnover (HSL and ATGL) have been reported to be more expressed in type I muscle 
fibers than in type II muscle fibers [155, 188, 272-275]. A study by Lillioja [276] 
performed decades ago showed a positive correlation between in vivo insulin sensitivity 
and type I fiber and an inverse correlation between in vivo insulin sensitivity and type IIx 
fiber from muscle biopsies. Other studies showed a lower fiber type I in obese T2D muscle 
than in obese and lean [277] or lower fiber type I in the insulin resistant group [272]. Type 
IIa and IIx was found to be higher in muscle of obese diabetic, diabetic and insulin 
resistant groups compared to the lean, obese, insulin sensitive groups [272, 277, 278]. A 
higher level of IIx was found for obese compared to lean muscle, and in support a 
positively correlation was found with BMI and fiber type IIx [279] and an inverse 
correlation between BMI and type I fibers was found [277]. All this indicates a strong 
connection between fiber type, obesity and insulin sensitivity. 
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Metabolic flexibility 
Skeletal muscle use both FAs and carbohydrate as fuel, but FAs predominates during 
fasting, while glucose dominates in the postprandial period (see Figure 7). Metabolic 
flexibility is defined as the muscle’s ability to change between predominantly FA oxidation 
in the fasting state and carbohydrate oxidation in the fed (insulin-stimulated) state. Loss of 
this capacity to switch easily between glucose and lipid oxidation was termed metabolic 
inflexibility by Kelley et al [280]. Obesity, insulin resistance, and T2D are associated with 
impaired postprandial switch from lipid to glucose oxidation [281, 282] (Figure 7). A 
reduced flexibility is thus been observed in association with insulin resistance and T2D in 
vivo [281-285]. Galgani et al [286] propose that metabolic inflexibility to glucose in type 2 
diabetic subjects is mostly related to defective glucose transport, but that impaired 
metabolic flexibility might be responsible for the accumulation of intramyocellular lipid 
and insulin resistance. Furthermore, high-fat feeding has also been associated with reduced 
metabolic flexibility in skeletal muscle from rats [247] and lower metabolic flexibility has 
been seen in vivo in obese individuals [281] and after three-week high fat diet in 
overweight men [287]. Clinical studies have shown that postprandial impairments in 
metabolic flexibility can be improved by weight loss [282, 284, 288, 289]. Further, ω-3 
FAs (e.g. EPA) have been observed to have a preservative effect on metabolic flexibility 
when co-administrated with thiazolidinediones in high-fat fed mice [290].  Subsequently, 
metabolic inflexibility could be due to both intrinsic and extrinsic factors.  
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Figure 7. Metabolic flexibility. Healthy skeletal muscle of lean subjects is metabolically flexible and has the 
ability to switch easily between oxidation of FAs (FAs) and glucose (Glc). During fasting, skeletal muscle of 
healthy, lean individuals (A) has a preference for FA oxidation, whereas glucose oxidation is suppressed. On 
the other hand, skeletal muscle of obese, metabolically inflexible individuals (B) has a blunted preference for 
FA oxidation and reduced suppression of glucose oxidation during fasting. After a meal, skeletal muscle of 
healthy, lean individuals (C) shifts to a preference for glucose oxidation, whereas FA oxidation is suppressed. 
In this situation, skeletal muscle of obese, metabolically inflexible individuals (D) shows less suppression of 
FA oxidation and blunted preference for glucose oxidation. Modified from [268, 283]. 
 
Interestingly, it has been observed that muscle cells isolated from healthy lean subjects 
and overweight/obese patients with/without T2D maintain these characteristics in culture 
[235, 236, 285, 291-293]. Ukropcova et al. [285] described metabolic switching in vitro in 
human myotubes as adaptability and suppressibility. Adaptability was defined as the 
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capacity of the cell to increase FA oxidation upon increased FA availability. Suppressibility 
was defined as the ability of acutely added glucose to suppress FA oxidation and may 
reflect the reverse Randle’s cycle [285]. 
Randle’s cycle describes the biochemical mechanism by which FA oxidation inhibits 
glucose utilization and vice versa in muscle [229]. Malonyl-CoA inhibits CPT1, thereby 
inhibiting entry and oxidation of FAs in mitochondria, explaining the inhibitory effect of 
glucose on FA oxidation (see Figure 9). The ability of FAs to suppress glucose oxidation 
may be mediated through inhibition of PDH by acetyl-CoA, as well as inhibition of 
glycolytic enzymes by cytosolic citrate (see Figure 6). Furthermore, AMPK may inhibit 
ACC and therefore decrease malonyl-CoA and its inhibitory effect on CPT1 [294] (see 
Figure 9).  An old theory is that insulin resistance occurs due to a defective Randle’s cycle 
[229]. However recent studies demonstrate that Randle’s cycle does not completely explain 
the effects of FA on glucose metabolism indicating that other mechanisms are also 
involved in the FA-induced insulin resistance [294, 295]. A new factor in regulating 
substrate switching and glucose tolerance is identified, CrAT. CrAT converts acetyl-CoA 
to acetylcarnitine ester, and seems to regulate mitochondrial and intracellular carbon 
trafficking [296]. Muoio et al proposed that CrAT eases Randle’s cycle, promotes 
metabolic flexibility, and enhances insulin action by permitting mitochondrial efflux of 
excess acetyl moieties that otherwise inhibit key regulatory enzymes such as PDH. 
 
The role of PPAR and LXR 
Peroxisome proliferator-activated receptors (PPARs) and liver X receptors (LXRs) both 
belong to the RXR heterodimer subfamily of nuclear receptors which act as transcription 
factors. PPARs play essential roles in the regulation of energy metabolism, while LXRs are 
important regulators of cholesterol, FA, and glucose homeostasis [297, 298]. LXRs and 
PPARs may also interact with each other (crosstalk) [299, 300]. 
PPARs have three different subtypes; α, δ/β and γ1,2 and the subtypes display different 
tissue specific expression and gene regulatory profiles [301]. PPARδ and PPARα-regulated 
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genes are involved in FA oxidation, whereas PPARγ is a key regulator of adipose 
development and lipogenesis [301] and whole-body insulin sensitivity.  PPARδ is the most 
abundant subtype in skeletal muscle [302, 303], and activation of PPARδ is reported to 
improve hyperglycemia and insulin resistance in humans [304, 305]. PPARδ may be 
activated by all FAs [305, 306], however they might be more strongly activated by UFAs 
than by SFAs [307, 308]. PPARγ may also be activated by all FAs [305], perhaps to a 
higher degree by UFAs [307, 308] or PUFAs [309]. PPARα is most likely activated by all 
FAs [305, 307, 308]. Furthermore, PPARs may also be activated by eicosanoids [305, 306, 
309]. Target genes of PPAR are e.g. genes involved in FA uptake and transport (FATP, 
FABPpm, CD36, ACSLs) and glucose uptake (GLUT4). In addition genes involved in FA 
oxidation (CPT1, Cyc1, PDK4), lipid storage (PLIN2, PLIN4, PLIN5), lipogenese (SCD1, 
FADS2), lipid turnover (DGAT, ATGL, HSL) and angiopoietin-like protein 4 (ANGPTL4) 
[310-316] are also found. However, not all of these are found as targets in muscle or in 
humans yet. ANGPTL4 is believed to be involved in regulating glucose homeostasis and 
lipid metabolism, in addition to angiogenesis, however little is known how exactly this 
occurs [311, 317, 318]. PPARδ activation with a selective agonist increased OA oxidation, 
PDK4, ANGPTL4, CPT1a, PLIN2 and CD36 expression; on the other hand, it decreased 
glucose oxidation in human myotubes [316]. 
PPAR gamma coactivator 1-alpha (PGC-1α) is an important regulator of 
gluconeogenesis, FA oxidation and adaptive thermogenesis [319] and is a “master 
regulator” of the coordination of mitochondrial biogenesis [320, 321]. PGC-1α is observed 
downregulated in skeletal muscle of prediabetic and diabetic individuals [322], while high-
fat feeding has been associated with increased PGC-1α expression [249, 323] in rat muscle. 
Overexpression of this gene resulted in an increase in GLUT4 expression [324] and 
treatments with a PPARγ agonist increased both PGC-1α and GLUT4 expression in 
myotubes [325]. Another study revealed that PGC-1α overexpression increased the 
oxidation rate of PA and mRNA expression of genes regulating lipid metabolism, 
mitochondrial biogenesis, and function in human myotubes. However, basal and insulin-
stimulated glucose uptake was decreased [326]. PPARδ may be a key regulator of skeletal 
muscle fiber type towards a higher expression in type I muscle compared with type II 
muscle fibers [327-329] and PGC-1α overexpression in human myotubes resulted in a 
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decreased expression of fiber-type gene marker for type IIA (MYH2) [326]. Adaptation to 
increased contractile activity involves conversion from type II to type I fibers [330, 331], is 
proposed to be a process driven by PGC-1α [332]. 
LXRs are important regulators of cholesterol, lipid and glucose metabolism [333]. The 
LXRβ isoform is ubiquitously expressed in adults [334], whereas the expression of LXRα 
is mainly restricted to tissues known to play an important role in lipid metabolism [335]. 
Agonists for LXRs include naturally occurring oxysterols [336] and the synthetic 
compound T0901317 [337], whereas the synthetic 22(S)-hydroxycholesterol has been 
shown to act as a LXR modulator on certain genes in myotubes [338]. In myotubes several 
lipogenic genes (SCD, FASN, ACSLs), lipogenesis, FA and glucose uptake (CD36 and 
GLUT4 expressions) and oxidation were increased after long-term T0901317 incubation. 
In addition, the number of LDs, as well as cell content of DAG and TAG, was increased 
after exposure to T0901317 in myotubes [338, 339], indicating an important role of LXR 
in energy metabolism in skeletal muscle.  
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Exercise and skeletal muscle 
Exercise in vivo has many beneficial effects, for instance in prevention of development of 
T2D and in improvement of insulin sensitivity in T2D patients already suffering from 
insulin resistance [289, 340, 341]. These positive effects are probably caused by an 
increased glucose disposal and glycogen storage in skeletal muscle tissue, as a single bout 
of exercise increases glucose uptake into contracting muscle via GLUT4 [341]. This 
benefit can be maintained in those who exercise regularly throughout their lifespan. 
Exercise-mediated enhancement of substrate oxidation is especially important in the 
treatment of obesity and T2D and an acute bout of exercise increases lipid oxidation in 
overweight and obese subjects [243, 342].  
Regular physical activity also increases the GLUT4 expression [343] and GLUT4 
overexpression in skeletal muscle has been found to increase both insulin- and contraction-
stimulated glucose transport and metabolism [91]. However, exercise may affect GLUT4-
regulated glucose uptake through a different signaling pathway than insulin involving 
AMPK activation [87, 96, 116]. There are indications that AS160 and TBC1D1 are 
regulated by exercise/muscle contraction through protein kinases, involving activation by 
AMPK, but not by Akt [87, 88] and glucose inactivates AMPK, perhaps as a feedback 
control [344] (see Figure 8). Further, a study observed an increased AMPK activity, 
AS160-Ser711, TBC1D1-Ser231/660 phosphorylation, but no increase in Akt or TBC1D1-
Ser700/Thr-590 phosphorylation, confirming the results that exercise-effects are not using 
the same pathway as insulin [345, 346]. Aguer et al found that AMPK protein level was 
lower in obese skeletal muscle compared to lean and obese with T2D skeletal muscle, 
while both Aguer et al and Bikman et al found that AMPK phosphorylation was similar in 
obese and lean muscle/myotubes [109, 143]. Furthermore, AMPK may exert stimulatory 
effects on different enzymes resulting in a less inhibited IRS and thereby also improving 
insulin signaling in that matter [347].  
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Figure 8. Model for contraction-stimulated glucose transporter 4 (GLUT4) translocation in muscle. 
Contraction leads to energy depletion (i.e., an elevated AMP/ATP ratio) and elevated intracellular [Ca2+] that 
again leads to activation of AMP-activated protein kinase (AMPK). Activated AMPK leads to Akt substrate 
of 160 kDa (AS160) and TBC1D1 phosphorylation at multiple phosphorylation sites and allows the 
conversion of less active GDP-loaded Rab to more active GTP-loaded Rab. The more active GTP-loaded Rab 
then allows GLUT4 storage vesicles to move to and fuse with the plasma membrane. Glucose may inhibit 
AMPK. The star represents a phosphorylation event.  
 
Another effect of endurance exercise is an increased proportion of type I muscles [107, 
167, 348], and PPARδ and PGC-1α may partially mediate these positive adaptions in 
skeletal muscle in response to exercise [301, 321, 326-329, 349, 350]. After exercise, 
PPARα, PPARδ, PGC-1α and PPAR targets such as PDK2 and PDK4 are increased [199]. 
Surprisingly, it has been shown that also subjects who exercise regularly (athletes) have 
elevated IMTG levels, despite a higher insulin sensitivity and higher oxidative capacity, 
compared to untrained persons [107, 162, 163], even when compared to T2D muscle fibers 
[163]. This is referred to as the “athlete’s paradox”. Some studies have also demonstrated 
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that training increases IMTG level [167, 289, 341, 348, 351]. In an in vivo study, exercise 
restored mitochondrial function, improved insulin-mediated glucose disposal and 
metabolic flexibility in type 2 diabetic subjects in the face of near-significantly increased 
IMCL content [289]. Moderate exercise also increased IMCL, oxidative capacity of 
muscle, and insulin sensitivity in previously sedentary overweight to obese, insulin-
resistant, older subjects [167]. The current paradigm is that regular exercise increases 
turnover and content of the IMTG pool, which prevents accumulation of lipotoxic 
intermediates [99, 107, 352]. In correspondence to this, DGAT1 expression increase in 
mouse and human skeletal muscle after exercise [353, 354]. However, in other studies this 
could not be reproduced [107, 186]. A six-week exercise study in obese subjects 
discovered both increased insulin sensitivity and IMCL in muscle biopsies post training, 
while DAG and ceramide levels decreased [167]. However, contradictory results from 
athletes on DAG level are reported [107, 111]. Moreover, athlete muscle was found to 
have more PLIN5 [107] and SCD protein expression [107, 111] and higher mitochondrial 
content [107]. Peters et al also found more PLIN5 in exercised muscle, which correlated 
with IMCL in lean and obese muscle and with mitochondrial density in obese muscle [171]. 
In contrast to endurance training, strength training does not lead to an increase in 
mitochondrial content in the skeletal muscle, yet insulin sensitivity increases also with this 
training modality [355].  
In addition to increased mitochondrial content after exercise [331], exercise also 
increases FA oxidation from IMTG stores during exercise [302, 341, 356]. ACC2 may be 
phosphorylated by AMPK and acetyl-CoA is converted to malonyl-CoA by ACC, and 
thereafter malonyl-CoA may inhibit CPT1 [294] (See Figure 9). In addition, AMPK 
protein level is highest in fiber type I muscle [357]. Contraction may also increase lipolysis 
by phosphorylation of HSL in skeletal muscle [190, 197] and AMPK activation is also 
reported to phosphorylate HSL and even override β-adrenergic stimuli on HSL activity 
[199, 200]. On the other side, this phosphorylation is observed not to influence HSL 
activation in skeletal muscle [358]. After exercise several genes were observed increased, 
however, Watt et al speculate that this increase might be a secondary effect due to 
increased epinephrine levels, not due to contraction [199], and this might also be the cause 
for HSL activation as well. In skeletal muscle, no effect on HSL protein content and 
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decreased HSL Ser565 phosphorylation after exercise has been found, but instead an 
increase in ATGL protein expression was observed. However, the level of CGI-58 was not 
changed by endurance exercise [186]. The upregulation of ATGL by exercise/in athletes 
has later been reproduced [107].  
 
Figure 9. Proposed signaling pathways for contraction-stimulated fatty acid (FA-CoA, green oval circle with 
blue tale) oxidation in muscle. Contraction through both energy depletion (i.e., an elevated AMP/ATP ratio) 
and elevated intracellular [Ca2+] leads to activation of AMP-activated protein kinase (AMPK). Activated 
AMPK leads to phosphorylation and deactivation of acetyl-CoA carboxylase (ACC). Activated ACC should 
have converted acetyl CoA to malonyl-CoA that inhibits carnitine palmitoyltransferase 1 (CPT1). However, 
this inhibition is prevented with phosphorylation of ACC and FA oxidation is increased (“FA ox”). The star 
represents a phosphorylation event.  
 
Skeletal muscle as an endocrine organ 
During the past decade, skeletal muscle has been identified as a secretory organ. The 
muscle secretome consists of several hundred secreted peptides [359], and this introduces a 
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new paradigm for understanding how muscles communicate with other organs. Myokines 
are peptides that are released by muscle fibers exerting autocrine, paracrine or endocrine 
effects. Myokines may balance and counteract the effects of adipokines and may mediate 
protective effects of muscular exercise with regard to diseases associated with a physically 
inactive lifestyle [360]. Some myokines exert their effects within the muscle itself, and for 
instance myostatin, IL-6 and IL-7 are involved in muscle hypertrophy and myogenesis 
[361, 362] and IL-6 are involved in AMPK-mediated fat oxidation [363, 364] (See Figure 
9). Furthermore, IL-6 from muscle may stimulate lipolysis in adipose tissue, while IL-6 
from adipose tissue may induce insulin resistance in muscle [365].  
By elevating circulating leptin concentrations to concentrations comparable with 
those of obese individuals, in vivo skeletal muscle signaling through the AMPK pathway 
was increased and caused an increase in FA oxidation in human and rodent skeletal muscle 
[366]. Steinberg et al 2006 [367] also found that leptin stimulates AMPK activity and FA 
oxidation in myotubes from lean subjects. In myotubes of obese subjects there was a 
blunted leptin-dependent activation of AMPK signaling. Furthermore, incubation of human 
skeletal muscle cells with adipocyte-conditioned media increased PA uptake, TAG content 
and DAG species, while decreased PA oxidation. Adipocyte-conditioned media alone 
increased CD36 protein levels and reduced insulin-stimulated phosphorylated Akt. Taube 
et al concluded that adipokines play a role in the pathogenesis of T2D due to an increased 
lipotoxic potential of PA [368]. 
IL-6 is a pleiotropic hormone and cytokine that has both pro- and anti-inflammatory 
actions and is up to 100-fold upregulated and released into the circulation by contracting 
muscle [365, 369, 370]. Acute treatment of rat L6 muscle cells with IL-6 increased both 
insulin-stimulated and basal glucose uptake [364] and contraction by electrical pulse 
stimulation (EPS) in C2C12 muscle cells increased IL-6 [371]. Furthermore, both IL-6 
mRNA expression [372] and protein release [372] were enhanced when glycogen levels 
were low, which suggests that IL-6 works as an energy sensor [359]. Interestingly, IL-6 
KO mice develop late-onset obesity and glucose intolerance [373]. However, whole-body 
glucose disposal, glucose uptake or endogenous glucose production was not affected by 
IL-6 infusion [363, 374].  
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Aims  
The overall aim of this thesis was to expand our knowledge on energy metabolism in 
human skeletal muscle cells in relation to type 2 diabetes (T2D), obesity and effects of 
dietary fatty acids and exercise in vitro. In particular the study concentrated on the 
elucidation of regulatory aspects of accumulation of fatty acids, and the connection with 
metabolic flexibility and glucose metabolism in skeletal muscle cells. The overall aim was 
broken down into four subthemes and the resulting data are presented as published papers 
and manuscript. 
 
• A study of the effect of different fatty acids on energy metabolism and metabolic 
flexibility. 
 
• A study on how a saturated fatty acid (palmitic acid) is metabolized differently 
from a monounsaturated fatty acid (oleic acid) with focus on lipid turnover 
 
• A study on the effect of extreme obesity and T2D on energy metabolism, lipid 
turnover and metabolic flexibility. 
 
• Finally, a study to establish and evaluate an in vitro model for exercise using 
electrical pulse stimulation. 
 
 
 
 
38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
39 
 
Summary of papers 
Paper I: Metabolic switching of human myotubes is improved by n-3 FAs.  
Skeletal muscle in lean, healthy individuals is characterized by metabolic flexibility; the 
ability to switch from predominantly lipid oxidation during fasting conditions to 
suppression of lipid oxidation and increased glucose oxidation in response to insulin.  
Obesity, insulin resistance, and T2D are associated with reduced lipid oxidation during 
fasting, impaired postprandial switch from lipid to glucose oxidation, and reduced capacity 
to increase lipid oxidation during exercise. The aim of the present study was to examine 
whether pretreatment with different FAs (PUFA, MUFA, SFA), as well as the LXR agonist 
T0901317, could modify metabolic switching of human myotubes.  
Myotubes were established from biopsy samples from M. obliquus internus 
abdominis of lean healthy individuals. Substrate-regulated flexibility was defined as the 
ability of the cells to increase the OA oxidation while changing from the “fed” (low FA, 
high glucose) to the “fasted” (high FA, no glucose) condition. Treatment with EPA 
increased suppressibility, the ability of glucose to suppress FA oxidation. Treatment with 
EPA, DHA and alpha-linolenic acid (ω-3 FAs) increased substrate-regulated flexibility of 
FA metabolism. Adaptability, the capacity to increase FA oxidation with increasing FA 
availability, was enhanced after pretreatment with EPA, LA (ω-6), and PA. T0901317 
counteracted the effect of EPA on suppressibility and adaptability, but it did not affect 
these parameters alone. EPA per se accumulated less in the cells; however, EPA, LA, OA, 
and T0901317 treatment increased the number of LDs in myotubes. Mitochondrial staining 
was independent of FA pretreatment. Microarray analysis showed that EPA regulated more 
genes than the other FAs (24 up, 98 down) and gene set enrichment analysis (GSEA) 
showed that only EPA induced pathways involved in carbohydrate metabolism and 
cholesterol biosynthesis.  
The present study suggests a favorable effect of ω-3 FAs, compared to other FAs, 
on skeletal muscle metabolic switching that might contribute to the beneficial effects 
observed after dietary intake of ω-3 FAs. We also suggest the use of the new parameter 
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substrate-regulated flexibility in functional studies of fuel selection and energy metabolism 
in cell cultures in addition to suppressibility and adaptability. 
 
Paper II: Palmitic acid follows a different metabolic pathway than oleic acid in human 
skeletal muscle cells; lower lipolysis rate despite an increased level of adipose triglyceride 
lipase.  
Development of insulin resistance and obesity is positively associated with dietary SFAs 
and negatively associated with MUFAs. To clarify aspects of this difference we have 
compared the metabolism of OA (MUFA) and PA (SFA) in human myotubes. 
 Myotubes were established from biopsy samples from M. obliquus internus 
abdominis and M. vastus lateralis of lean healthy individuals. We observed that PA had a 
lower lipolysis rate than OA, despite a more than two-fold higher protein level of ATGL 
after 24 h incubation with PA. PA was less incorporated into TAG and LDs, had a higher 
DAG/TAG ratio and more incorporated into phospholipids and cholesteryl ester after 24 h. 
In support, incubation with compounds modifying lipolysis and reesterification pathways 
suggested a less influenced PA than OA metabolism. In addition, PA showed a lower 
accumulation than OA, though PA was oxidized to a relatively higher extent than OA. 
Microarray based on mRNA samples and GSEA revealed that 24 h of PA treatment 
upregulated lipogenesis and FA β-oxidation and downregulated oxidative phosphorylation 
compared to OA. In addition, the DGAT-1 inhibitor A922500 was used, as far as we know, 
for the first time and reduced TAG formation by about 90 % and increased oxidation of 
OA about 2-fold. Mitochondrial staining was independent of OA or PA pretreatment. The 
differences in lipid accumulation and lipolysis between OA and PA were eliminated in 
combination with EPA.  EPA upregulated cholesterol biosynthesis and pathways involved 
in carbohydrate metabolism in comparison with OA.  
In conclusion, this study reveals that the two most abundant dietary FAs are 
partitioned toward different metabolic pathways in muscle cells, and this may be relevant 
to understand the link between dietary fat and skeletal muscle insulin resistance. 
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Paper III: Myotubes from extremely obese non-diabetic donors have higher ability for 
lipid accumulation and lower lipolysis compared to extremely obese type 2 diabetic 
donors. 
Obesity is strongly associated with insulin resistance and T2D and about 80 % of patients 
with T2D are classified as overweight. However, a study at The Morbid Obesity Center in 
Tønsberg, Norway revealed that only about 1/3 of extremely obese patients undergoing 
bariatric surgery have T2D. This indicates that many extremely obese individuals possess 
certain characteristics that protect them against developing T2D. We hypothesized that 
some of these characteristics could be related to differences in skeletal muscle energy 
metabolism. 
Myotubes were established from biopsy samples from M. obliquus internus abdominis 
of lean healthy (BMI 22 ± 3 kg/m2), extremely obese non-diabetic (BMI 44 ± 7 kg/m2) and 
extremely obese subjects with T2D (BMI 43 ± 6 kg/m2). Decreased insulin sensitivity was 
observed in myotubes from extremely obese subjects with T2D, assessed as decreased 
deoxyglucose accumulation and near-significant decreased phosphorylation of Akt. 
Lipolysis was about 60 % lower, and FA accumulation, mitochondrial staining and 
adaptability was higher in myotubes from extremely obese non-diabetic subjects compared 
to extremely obese subjects with T2D. A two-fold increase in FA oxidation and a lower 
glucose suppression of FA oxidation was observed in cells established from extremely 
obese subjects compared to cells from lean controls.  
Myotubes from extremely obese non-diabetic donors had higher ability for lipid 
accumulation and lower lipolysis compared to diabetic donors. Our hypothesis is that by 
storing more lipids, the formation of lipotoxic intermediates that can interfere with insulin 
signaling could be prevented. Myotubes from extremely obese non-diabetic donors had 
higher FA oxidation and mitochondrial staining, whilst a lower suppressibility of FA 
oxidation than lean donors. This might be caused by a compensatory reaction in vivo to 
handle a higher availability of lipids in the extremely obese condition and this occurs at the 
expense of suppressibility. This study provides results that might contribute to more 
knowledge of how some extremely obese are protected against development of obesity-
related T2D.   
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Paper IV: Electrical pulse stimulation of cultured human skeletal muscle cells as an in 
vitro model of exercise. 
Physical exercise leads to substantial adaptive responses in skeletal muscles and regular 
physical activity plays a central role in both prevention and improvement of many chronic 
diseases, as T2D and obesity, and increased life expectancy. Since exercise induces major 
systemic responses, underlying cellular mechanisms are difficult to study in vivo. It was 
therefore desirable to develop an in vitro model that would resemble training in cultured 
human myotubes.  
Myotubes were established from biopsy samples from M. obliquus internus 
abdominis of lean healthy individuals. Electrical pulse stimulation (EPS) was applied to 
adherent human myotubes for 5 min - 48 h. High-frequency, acute EPS increased glucose 
uptake and lactate production, while cell contents of both ATP and PCr decreased. Chronic, 
low-frequency EPS increased oxidative capacity of cultured myotubes by increasing 
glucose metabolism (uptake and oxidation) and complete OA oxidation. Mitochondrial 
staining was doubled after 48 h of chronic, low-frequency EPS. Gene expression level of 
PDK4 was significantly increased in EPS-treated cells, while mRNA expressions of IL-6, 
Cyc and CPT1b tended to increase. Protein expression of a slow fiber type I marker 
(encoded by MYH7) was increased in EPS-treated cells.   
Even though it is difficult to directly compare effects of in vivo exercise to the 
observed effects in our model of EPS in cultured human myotubes, several of our 
observations display important aspects of the in vivo effects of exercise. We observed 
important functional changes in cell culture: improved lipid oxidation and glucose 
metabolism, as well as a fiber-type switch. Our results imply that in vitro EPS (acute, high-
frequent as well as chronic, low frequent) of human myotubes may be used to study the 
effects of exercise on the cellular level. 
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Methodological considerations 
Skeletal muscle cells (myotubes) 
Satellite cells can be isolated from skeletal muscle biopsies, activated to proliferating 
myoblasts and differentiated into multinuclear myotubes in culture [375]. These cell 
cultures represent the best available model system to intact human skeletal muscle, which 
can be modulated in vitro. In the in vitro system, the influence of physiological factors as 
hormonal concentrations, physical activity and neural input are removed, and remaining 
differences should be attributed to genetic or epigenetic origins [376]. Advantages of this 
system include having the extracellular environment that can be precisely controlled and 
that the cells are not immortalized, thereby offering the possibility of studying innate 
characteristics of the donor. Moreover, it has been shown that human myotubes display the 
same phenotype as intact muscle in vivo [377, 378], perhaps due to epigenetic changes as 
DNA/mRNA methylation, histone modifications or differentiation patterns. The muscle 
cells used in this thesis are derived from biopsies from lean healthy donors at Oslo 
University Hospital, Oslo, Norway, taken during kidney donation surgery.  The muscle 
cells derived from extremely obese donors came from The Morbid Obesity Center in 
Tønsberg, Norway, and are from biopsies retrieved during bariatric surgery. 
The fast and slow fibers are present in skeletal muscle in vivo [379], and when 
grown in culture, human satellite cells mature to myotubes that express fiber types I, IIa 
and IIx (Paper IV, [380]). However, they seem to depend more on glycolytic (type II 
fiber) than oxidative metabolism (type I fiber) [377, 379]. Compared with myoblasts, the 
protein expression pattern of myotubes exhibits a higher resemblance to adult skeletal 
muscle, and myotubes are therefore preferred for experimental use [381]. Furthermore, the 
ratio GLUT1/GLUT4 is increased in human myotubes compared with skeletal muscle [94, 
382], resulting in a decreased insulin responsiveness of glucose transport. Even though the 
effect of insulin is decreased in myotubes, the responsible molecular mechanisms of 
glucose transport are observed to remain the same as in vivo [94]. Muscle contraction also 
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stimulates translocation of GLUT4 and increases glucose uptake (see Figure 8), and there 
have been some studies on human myotubes that have observed a response to electrical 
pulse stimulation (EPS) in a similar way as to exercising muscle in vivo (Paper IV, [380]). 
Insulin stimulation also increases glycogen synthesis about 2-fold in human myotubes, 
which is similar to in vivo observations [94, 325, 383]. Together, these observations imply 
that glucose metabolism, insulin signaling and responses to exercise are very similar in 
human myotubes as in skeletal muscle in vivo, confirming the dependability of human 
myotubes as a model system. Furthermore, the capacity to oxidize fat has been compared 
between homogenates of donor muscle biopsies from healthy subjects and their 
corresponding derived muscle cell cultures [384, 385]. The oxidation rate of PA [384, 385] 
and the activity of citrate synthase [385] were comparable. In another study it was 
observed that a low lipid oxidation in vivo, represented by a high respiratory quotient (RQ) 
measured during fasting, was reflected by a low lipid oxidation in vitro [236]. Moreover, in 
myotubes established from young healthy subjects, in vitro adaptability was related to a 
change in RQ during hyperinsulinemic euglycemic clamp (a measure for metabolic 
flexibility in vivo) [285].  
There are also limitations to the model. As previously mentioned, compared to the in 
vivo situation, the insulin-stimulated glucose uptake in primary human myotubes is 
relatively low and there is a dominant fiber type II expression in myotubes. A cell model 
that depend more on oxidative metabolism would therefore be desirable to resemble in vivo 
situation to a higher degree. Cultivation conditions may contribute to this, as for instance 
by EPS, PPAR activation, or by exchanging glucose with galactose in the cultivation 
media (Paper IV, [316, 380, 386]). Moreover, a direct comparison of mRNA expression in 
muscle biopsy materials with myotube cultures show that most genes studied was 
markedly higher expressed in biopsies than in cells (Paper III), the only exception were 
the LD protein PLIN3. In addition, a study revealed that in myotubes PLIN2 and PLIN3 
dominates, while in biopsy PLIN2, PLIN4 and PLIN5 dominates [154]. Moreover, in 
myotubes established from young healthy subjects, the suppressibility in vitro was 
inversely related to insulin sensitivity and change in RQ during a hyperinsulinemic 
euglycemic clamp (measure of metabolic flexibility) in vivo, despite a positively 
correlation with adaptability.  These observations might be inappropriate to compare with 
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the studies in this thesis, as the in vivo experiments were done in the presence of insulin 
[285], whereas the in vitro experiments were done in the absence of insulin. However, 
more studies need to be performed to conclude on this. Finally, taking these limitations 
into consideration, there are many studies to be performed in cultured skeletal muscle cells, 
especially on genetic and epigenetic changes.   
 
Donor characteristics  
Donors that have contributed with biopsies were adults of different ages (26-70 years), 
both genders, as well as they may have possessed different diseases or conditions. They 
were on average 40-50 years old with majority of women (≈ 70 %). The lean donors used 
in this thesis had an average BMI of 24 kg/m2, while the extremely obese donors had an 
average BMI of 44 kg/m2 and a lower HDL, whilst higher TAG values and blood pressure 
than the lean. On average fasting glucose and HbA1c was normal for the lean and the 
extremely obese non-diabetic donors, while for the extremely obese T2D donors the 
average value was above reference values (see Table 1). In addition, 72 % of the extremely 
obese and 5 % of the healthy lean donors had the metabolic syndrome. 
Table 1. Donor characteristics for the three donor groups Lean (healthy), EO-nD (extreme obese non-
diabetics) and EO-T2D (extreme obese with type 2 diabetes) used in this thesis. Mean are presented. 
#Significantly different from L. *Significantly different from EO-nD. BMI; body mass index, HbA1c; 
glycosylated haemoglobin, HDL; high-density lipoprotein, LDL; low-density lipoprotein, - ; no data, TAG; 
triacylglycerol.  
 
Age 
(yrs) 
BMI 
(kg/m2) 
Fasting 
glucose 
(mmol/l) 
HbA1c 
% 
Insulin 
(pmol/l) 
Blood 
pressure 
(mmHg) 
HDL 
(mmol/l) 
LDL 
(mmol/l) 
TAG 
(mmol/l) 
Total 
cholesterol 
(mmol/l) 
Lean 48 24 5.0 - - 130/75 3.0 - 0.9 5.1 
EO-nD 40 44# 5.0 5.4 97 140/84# 2.8# 1.2 1.6# 4.7 
EO-T2D 49* 43# 7.6* 7.1* 78 139/80# 2.4# 1.1 1.8# 4.4 
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Age influence 
Increasing age is associated with muscle fatigue, atrophy or sarcopenia [387, 388], 
oxidative damage to mitochondrial DNA [389-391], reductions in mitochondrial content 
[392], function [393], in addition to a reduced insulin sensitivity [388, 394, 395]. Exercise 
may prevent age-related effects and perhaps increase life span [395-398] and an age-
related decline in mitochondrial oxidative capacity or content and DNA was absent in 
endurance-trained old subjects [396, 398]. However, Lanza et al [396] concluded that old 
age, rather than lack of exercise or physical activity, is the cause for mitochondrial changes 
and Karakelides et al [399] stated that age-related decrease in muscle mitochondrial 
function is not related to obesity or insulin sensitivity. In contrast, it is hypothesized that 
obesity rather than age per se is the primary determinant of age-related declines in insulin 
sensitivity [394]. Moreover, a few studies has shown that IMTG stores increase with 
increasing age [400] and that total fiber area and number of type II fibers  are inversely 
related to age [401], in addition to that skeletal muscle PPARδ decline with age [402]. In 
this thesis, the donors were mostly under the age of 60 years and donors of both old and 
young age were merged. 
Furthermore, adult stem cells are known to have a finite replication potential and 
human myotubes from myoblast cultures undergoing senescence exhibit defects in glucose 
and lipid metabolism. In a study muscle biopsy-derived human satellite cells were grown at 
different passages and differentiated to human myotubes in culture to analyze the 
functional state of various carbohydrate and lipid metabolic pathways. A number of 
cellular functions were altered as the proliferative potential of myoblasts decreased with 
increasing passage number. The capacity of myoblasts to fuse and differentiate into 
myotubes was reduced, and metabolic processes in myotubes such as glucose uptake, 
glycogen synthesis, glucose oxidation and FA β-oxidation became gradually impaired. 
Late-passage, non-proliferating myoblasts cultures showed strong senescence-associated β-
galactosidase activity, indicating that the observed metabolic defects accompany the 
induction of a senescent state [403]. However, the numbers of passages were kept within 
the normal response in this thesis. 
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Gender influence 
Whole-body resting energy expenditure and the mass of skeletal muscle are greater in men 
than in women [404] and in vivo whole body differences in glucose/lipid metabolism does 
exist between men and women [405]. Women are found to have higher expression levels 
of genes involved in lipid storage and turnover (IMCL, PLIN2-5, HSL), fatty acid uptake 
(CD36), insulin sensitivity (GLUT4, IR (insulin receptor), Akt, phosphorylation of Akt) 
and higher level of muscle fiber type I than the men [171, 406-414]. However, a study 
exploring the protein expression of PPARδ and genes that are regulated by or related to 
PPARδ (PPARα, PGC-1α, AMPKα, CD36, CPT1, COXIV)[415], as well as enzyme 
activity of citrate synthase and cytochome c oxidase [416] after exercise; no gender 
differences were observed. Gene expression of several genes involved in glucose and lipid 
metabolism has also been observed to be higher in skeletal muscle biopsies from female 
versus male donors, but these were unaltered in cultured myotubes in the same study, 
indicating the importance of hormones on these processes [417]. An important additional 
observation is that the expression patterns of fiber type markers seem to be the same in 
myotubes from male and female donors [379].  Thus, in the studies included in this thesis, 
the donors of both genders were merged. 
 
Methods used to measure energy metabolism 
The main methods in this thesis used radiolabelled energy substrates, mainly glucose and 
different FAs, added to the cell culture media to study different aspects of energy 
metabolism. Wensaas et al have previously developed methods for studying live substrate 
accumulation (scintillation proximity assay, SPA) and oxidation (substrate oxidation assay) 
with cultured cells [418].  Substrate oxidation assay was also used to measure in vitro 
metabolic flexibility [419]. Wensaas et al and Corpeleijn et al have previously used the 
SPA method in human skeletal myotubes and similar results in lipid accumulation is 
observed if cells are lyzed and remaining radioactivity is measured (Paper II and III, 
[236, 418]). In this thesis SPA was used with both lipid accumulation and lipolysis 
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experiments. SPA was first performed with radiolabelled FA present where the 
accumulation increased until steady state level after 24 h [236]. Therefore, the experiments 
in this thesis were performed using the same concentration of FA and a pre-incubation 
period up to 24 h. Afterwards SPA was performed without FA present in the cultivation 
media where the decline in radiolabelled FA represented a measure of lipolysis.  This 
corresponded with incline in radiolabelled FA released to the cultivation media measured 
as remained radioactivity in the cultivation media. The assumption for this method is that 
most of the lipids accumulate in LD. An inhibitor of ACSL, triacsin C, was used to inhibit 
reesterification and it would therefore reflect more selectively lipolysis. Earlier reports in 
human skeletal myotubes have shown that TAG synthesis is efficiently blocked with 
incubation of 10 μM triacsin C [184, 420]. However, triacsin C may inhibit several ACSLs 
and ACSLs may also catalyze other reactions. An example for this is shown as decreased 
OA oxidation with triacsin C incubation is presented in Paper II. However, triacsin C 
increases lipolysis about 2-fold (Paper II and III).  Incubation with triacsin C and 
measured TAG or fluorescent staining and quantification of LDs after OA exposure, 
revealed a triacsin C-induced reduction of 25 % and 70 %, respectively (Figure 10). 
Reesterification was measured as the difference between with and without triacsin C 
incubation [421].  
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Figure 10. Incorporation of OA into triacylglycerol (TAG) (measured by Thin Layer Chromatography, N=3, 
*p<0.05 vs control) and number of lipid droplets (LDs) per nucleus (measured by live cell imaging, N=1) in 
human skeletal muscle cells after exposure to triacsin C after 24 h of incubation with 100 µM oleic acid. 
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The cells were also incubated with fluorescent substances that are known diffuse 
through the plasma membrane and bind to intracellular organelles. After excitation of the 
fluorophore, the emitted light can be used as a quantitative measure. In this thesis, the live 
human skeletal muscle cells have been labeled with Hoechst 33258, MitoTracker®Red FM 
and Bodipy 493/503. Hoechst 33258 binds to double stranded DNA, and is well known as 
a quantitative measure for DNA.  Bodipy 493/503 is a lipophilic dye that accumulates 
within non-polar neutral lipids and is rather specific for LDs in cells [422]. 
MitoTracker®Red FM is a fluorescent dye that contain a mildly thiol chloromethyl moiety 
for accumulation within active mitochondria. There are, however, controversies regarding 
the latter dye’s limitation as a specific marker, for instance its dependence on membrane 
potential and oxidative capacity, and interpretations should be carried out with caution 
[423]. In Paper III and Paper IV we observed an increased staining of MitoTracker®Red 
FM in parallel with higher OA oxidation. At the same time in Paper III we show that there 
is less MitoTracker®Red FM regardless of similar oxidation and in Paper I and II 
treatment with different FAs did alter oxidation but not MitoTracker®Red FM staining. 
Thus, this dye seem to stain mitochondria independent of oxidation status in skeletal 
muscle cells and therefore possibly independent of membrane potential, implying that,  
limited to these cells and our conditions, it is a good measure of mitochondrial content. 
Mitochondrial content may also be measured as citrate synthase activity, cardiolipin 
content or as mitochondrial DNA content [424]. In support of our conclusion, citrate 
synthase activity and MitoTracker®Red FM intensity have the same pattern in our results 
(Paper IV). These dyes have been widely used in cell lines and tissue, but as far as we 
know, the use of these mitochondria and LD dyes for live cell imaging have not been 
reported previously in cultured human skeletal muscle cells (representative images Figure 
11).   
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Figure 11. A representative image of mitochondria, LDs and nuclei in human skeletal muscle cells. 
Mitochondria are stained by MitoTracker®Red FM (red), LDs by Bodipy 493/503 (green) and nuclei by 
Hoechst 33258 (blue). The image to the left is acquired by a fluorescence microscope (20 x objective, scale 
bar 50 µm), while the image to the right is from another experiment using a confocal fluorescence 
microscope (40 x objective) ant there is no nuclear staining (nuclei as “black holes”). 
The image acquisition and analysis was automated and the images are taken randomly, 
avoiding the potentially biased human factor. The autofocus was set for the Hoechst 33258 
channel to orient around the middle of the cells. The microscope set up had a temperature 
and a CO2 enrichment incubator for long-term live imaging so the cells kept healthy during 
image acquisition. Standard filter sets optimized for Hoechst 33258 (350 nm), Bodipy 
493/503  (488 nm), and MitoTracker®Red FM (594 nm) were used so that the excitation 
and emission should not overlap for the chosen dyes and minimizing bleed-through. 
Images were made at 5x5 or 6x6 positions from the middle of the well to cover most of the 
well surface (25-36 positions per well). We used the background-subtracted maximal 
intensity projection from 7-12 images taken in z-direction, 1 μm apart, to include the whole 
cell.  The images were analyzed and quantified using analysis software, which used an 
edge detection algorithm for object segmentation (see Figure 12) and the analysis was 
optimized for each experiment after examining at least 10 images. After analysis the 
images were visually examined and obvious artifactual image abnormalities were 
excluded. In the end about 200-400 images were used per parameter, giving good 
statistical data. The main possible source of error with this technology remains specificity 
of the staining agents and therefore we also used different biochemical methods to back up 
the fluorescence data. 
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Figure 12. Raw images with background staining (left image) that demonstrate the quantification of LDs 
(green) in blue circles (right image). Nuclei are stained in blue. These images are taken with a fluorescence 
microscope, 60 x objective, zoom 2x.  
 
There are two major stimuli that are associated with physical exercise; electrical 
and mechanical signals. Motor neuron activities generate electrical signals, while 
stretching of muscle fibers are mechanical signals. Excitation of muscle cells causes 
contraction and skeletal muscle cells contract when they are stimulated either via a nerve 
or electrically. Excitation-contraction has many short-and long-term effects on muscle cell 
function. An in vitro model that simulates exercise would be beneficial to explore effects 
of training and to identify training effects with regards to treatment against T2D and 
obesity. The model has previously been performed in myotubes from different species 
giving exercise-like effects [371, 380, 425-427].  In this thesis the human cells were 
stimulated via carbon electrodes either by applying acute, high-frequency EPS (pulse trains 
of bipolar pulses 100 Hz for 200 ms given every 5th s, 30 V, for 5-60 min) to simulate a 
single bout of exercise or by applying chronic, low-frequency EPS (single, bipolar pulses 
of 2 ms, 30 V, 1 Hz continuously for 24/48 h) to simulate regular exercise (Paper IV).  
Microarray for gene expression was assessed from isolated RNA samples and Gene Set 
Enrichment Analysis (GSEA) was performed for functional analysis of changes in gene 
expression (Paper I and II). Arrays for analyzing gene expression generates a huge 
amount of data, and is therefore highly valuable as a screening tool. However, there is a 
risk for false positive findings and the data must be carefully interpreted using advanced 
statistical tools. Significantly regulated genes by the FAs from the microarray analysis 
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described in Paper I are presented in Appendix I and all microarray data are submitted to 
Gene expression omnibus (GSEE18589). GSEA is focused on predefined gene sets, that is, 
groups of genes that share biological function, chromosomal location, or regulation. The 
functional catalogue [428] was modified to contain 505 well-defined biochemical, 
metabolic, and signaling pathways compiled from the following publicly available, curated 
databases: Biocarta, GenMAPP [429], Kyoto Encyclopedia of Genes and Genomes [430], 
Sigma-Aldrich pathways, and Signal Transduction Knowledge Environment. The 
advantage of this method is that it is unbiased because a score is calculated based on all 
genes in a gene set. In this thesis the microarray data was related to BSA (no fatty acid) 
(Paper I, Appendix I) or OA (Paper II) treatment as a control. 
Western blotting technology was applied for investigation of amount of expressed 
protein and phosphorylation of proteins. This allows us to detect post-translational 
modification, however it is a semi-quantitative technique and highly dependent on the 
quality of the antibodies. Overall, the methods used in the studies in this thesis are mostly 
radiolabelled tracer studies and fluorescent staining in addition to gene and protein 
expression to describe the processes in the cell. This combination is beneficial to cover the 
many aspects of regulation in a cell.  
 
Data analysis and statistics 
The most used statistical method in this thesis is the two-tailed Student´s t-test. The 
criterion of this test is that the data needs to be normal distributed. It may test if two 
distributions are equal (unpaired) or if the difference of two responses has a mean value of 
zero (paired). In the studies in this thesis a two-tailed unpaired or paired test was chosen 
depending on the experimental set up. Treatments within the same donor were tested with 
paired t-test, while when comparisons were made across donors or donor-groups they were 
tested with unpaired t-test. For correlation studies, Spearman correlation analysis was 
performed. Spearman is a non-parametric measure of statistical dependence between two 
variables. It assesses how well the relationship between two variables can be described 
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using a monotonic function. A perfect Spearman correlation of +1 or −1 occurs when each 
of the variables is a perfect monotone function of the other and the Spearman’s coefficient 
(ρ) defines the strength of the correlation. Linear mixed model (LMM) analysis was used 
in time-dependent experiments. Furthermore, LMM were used to compare the differences 
between conditions with within-donor variation and simultaneously compare differences 
between groups with between-donor variation. The LMM include all observations in the 
statistical analyses and at the same time take into account that not all observations are 
independent. For the mRNA expression data, significant difference was defined as two 
times or half expression of baseline in Paper III, but t-test was performed in the other 
papers. In experiments where there were three experimental groups, data were analyzed 
using non-parametric Kruskal-Wallis test (one-way ANOVA) (Paper IV). In experiments 
where EPS-treatment versus unstimulated control cells were compared, non-parametric 
Wilcoxon matched pair tests were performed, since the number of observations were few 
and normal distribution could not be assumed (Paper IV). All values are reported as 
means ± SEM if not stated otherwise. The value N represents the number of different 
donors used each with at least duplicate samples. Bonferroni correction was applied for 
multiple comparisons. Differences were considered significant when p < 0.05 and GSEA 
operated with a FDR < 0.2. 
 
 
 
 
 
 
 
 
 
54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55 
 
Discussion and Conclusion 
In this thesis energy metabolism has been examined in myotubes established from lean 
healthy, extremely obese non-diabetic and extremely obese T2D donors. Lean myotubes 
were treated with various fatty acids (SFA, MUFA, and PUFA) to explore possible 
different effects on metabolism and electrical pulse stimulation (EPS) to simulate exercise.  
 
Lipid storage and turnover 
Lipid accumulation was lower in PA-treated human skeletal muscle cells compared to 
UFA (EPA/LA/OA)-treated cells (Paper I and II). It is hypothesized that DGAT 
expression was dependent on the degree of FA saturation [431] and a study found that 
DGAT1 appeared to prefer oleoyl-CoA over palmitoyl-CoA [432], however they used 
other cell models, but this might be part of the explanation for different storage of FAs. In 
addition DGAT is a PPAR target [310, 316], and UFAs might act as stronger PPAR 
agonists than SFAs [307, 308]. Finally the DGAT inhibitor increased oxidation of OA to a 
higher degree than oxidation of PA (Paper II), indicating a more influenced OA 
metabolism. 
Lipolysis was lower, while lipid accumulation was higher in non-diabetic cells 
compared to diabetic while the mRNA expression of PLINs, HSL and ATGL was similar 
(Paper III). The hypothesis was that the cells from non-diabetics stored more lipids and 
this protected against generation of lipotoxic intermediates that might interfere with insulin 
signaling. In support of this hypothesis, we observed that PA upregulated ATGL protein 
content and the DAG/TAG ratio was higher in comparison to OA (Paper II).  This is in 
correspondence with that ATGL-KO mice had a lower lipolysis, higher accumulation of 
TAG but a higher glucose uptake in skeletal muscle [208], while ATGL-deficient animals 
had enhanced insulin sensitivity [209]. However, in contrast, a higher ATGL protein 
expression is found in athlete muscle or after exercise [107, 186]. This indicates a complex 
regulation, and the discrepancy between lipid turnover and mRNA/protein lipase 
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expression may be due to β-adrenergic stimuli [196-198], translocations [195, 433], post-
translational modifications [421] (phosphorylations [198, 215]), in addition to being 
influenced by presence of co-factors [184] or inhibitors [205] suggesting that regulation of 
their activity may be on these levels. 
MUFAs or PUFAs (as OA and EPA) are found to have positive effects or to counteract 
PA’s negative effects on glucose metabolism in rat or human myotubes [434-437]. Previous 
studies revealed that PA incubation did not increase IMCL, but reduced phosphorylation of 
Akt, though OA treatment increased IMCL, but did not affect Akt phosphorylation. Co-
incubation with these two FAs resulted in rescued insulin sensitivity and an increased 
IMCL [437].  Furthermore, EPA co-incubation with OA/PA eliminated the differences 
between OA and PA treated cells with respect to lipid accumulation and lipolysis (Paper 
II). This was in accordance with previous observations that EPA increased PA or OA-
derived TAG in human skeletal muscle [183, 438]. In correspondence with this, EPA pre-
treatment increased the number of LDs in lean myotubes compared to PA pre-treatment, 
despite a lower cellular accumulation. EPA pre-treatment also increased accumulation of 
OA compared to OA/PA pre-treatment (Paper I).  Furthermore, incubations of 
OA/PA/EPA revealed a higher re-esterification rate of OA and PA in the presence of EPA 
(preliminary data from our lab). Addition of a β-adrenergic agonist increased OA lipolysis, 
and this indicates that adrenergic stimulus is involved in regulation of skeletal muscle cell 
lipolysis (Paper II), as previously seen for HSL in skeletal muscle [197, 198, 273]. EPA 
treatment did however down-regulate the ADRB2 gene in comparison with BSA (no fatty 
acid) treatment in myotubes (Appendix I). The ADRB2 gene codes for the β2-adrenergic 
receptor and this might contribute to the explanation on EPA’s effect on lipid accumulation. 
In line with this, a study in cultured rat adipocytes has shown that EPA decreased lipolysis 
in an AMPK-dependent manner [439]. On the other hand, this might be a mechanism 
through PPARs, as PUFAs might be stronger agonists than the other FAs [309]. Therefore, 
EPA’s elimination of OA/PA difference might have been caused by increased PA’s re-
esterification, inhibition of lipolysis and/or via PPARs activation that prefer PUFAs before 
SFAs as agonists. Additionally, EPA is precursors of anti-inflammatory eicosanoids [78] 
as well as membrane alterations [79] that may have played a role in EPA´s beneficial 
effects. 
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Exercise has been found to increase DGAT1 [353, 354], lipolysis [197, 198, 273] and 
lipid storage in skeletal muscle [167, 348, 351] and exercise was also associated with 
involvement of PPARδ [440]. In accordance to this, the number of LDs increased by about 
1.9-fold, however not significantly, after EPS in myotubes (Figure 13), despite a similar 
cellular lipid accumulation (Paper IV). Furthermore, a LXR agonist also increased the 
number of LDs and OA accumulation in lean healthy myotubes ([338, 339], Paper I). The 
beneficial effect of increasing lipid accumulation (or decreasing lipolysis) in myotubes by 
EPS, EPA or LXR agonists treatments may perhaps be to protect against formation of 
lipotoxic intermediates. This possibility needs to be further elaborated.  
Un
sti
mu
lat
ed
 EP
S
0
100
200
300
N
um
be
r 
of
 li
pi
d 
dr
op
le
ts
 p
er
 n
uc
le
us
re
la
te
d 
to
 u
ns
tim
ul
at
ed
 c
el
ls
  
Figure 13.  Lipid accumulation in lipid droplets (LDs) in myotubes. Human skeletal muscle cells after 48 h 
electrical pulse stimulation (EPS) were stained and LDs and nuclei quantified. Results are presented as 
number of LDs per nucleus, mean±SEM, related to unstimulated, N=6 donors, two-tailed, paired t-test, 
p=0.12.   
 
PLIN2 and PLIN3 are the most abundant PLINs in cultured skeletal muscle cells [154] 
and have also been examined in this thesis. Treatment with PA did not differ from 
treatment with OA with regards to neither mRNA nor protein expression of the two PLINs 
(Paper II). Additionally, no difference in mRNA expression of these PLINs was found 
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between lean, extremely obese non-diabetics or diabetics (Paper III). Though, 
OA/PA/LA/EPA exposure increased the PLIN2 mRNA expression ([154, 158], Paper I 
and III), which might reflect that these FAs are activators of PPARs, as PLIN2 was 
observed as a PPARδ target [310, 316]. An “exercise mimetic” treatment of myotubes with 
forskolin and ionomycin to activate PKA and Ca2+ signaling pathways is previously seen 
to increase PLIN2 and PLIN3 expression in myotubes [441] and endurance training 
enhanced mRNA expression of PLIN2 and PLIN3 in muscle biopsies [154]. PUFA has 
also been observed to be more efficient than shorter FAs at stimulating PLIN2 mRNA 
expression in a human placental choriocarcinoma cell line and in primary human 
trophoblast [442]. However, microarray/mRNA expression studies indicate that the mRNA 
expression of PLIN2 after EPA treatment is increased compared to BSA, but not compared 
to OA ([183], Paper I, Appendix I) and that EPS does not alter PLIN2 or PLIN3 mRNA 
expression (microarray, preliminary data from our lab).   
 
Oxidation and Metabolic flexibility 
On energy demand, LDs may undergo lipolysis and make FAs available for oxidation in 
the mitochondria.  PA oxidation was higher than OA oxidation in myotubes, and EPS 
increased both OA and glucose oxidation (Paper II and IV). The EPS-stimulated cells had 
a tendency towards an upregulation of CPT1b and Cyc1 mRNA expressions, perhaps due 
to PPARδ activation that could explain the increased oxidation [310, 312, 314], in addition 
to mechanism shown in Figure 9 (Paper II and IV). This was not observed for PA-treated 
cells (data submitted to Gene expression omnibus (GSEE18589)), however EPA and PA 
did upregulate the β-oxidation pathway (Paper I and II). EPA has earlier been reported to 
increase incomplete PA oxidation in human skeletal muscle cells [183].  In this thesis, 
EPA- and PA-treated cells had a higher incomplete oxidation compared to OA-treated, 
perhaps explained by EPA’s upregulation of ACC (Paper I and II). EPS did not influence 
this parameter (Paper IV), indicating that the ratio complete/incomplete oxidation is 
different between these stimuli and might contribute to the explanation of why diet and 
training have somewhat different outcome. The extremely obese myotubes had a higher 
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FA oxidation than the lean myotubes (Paper III). This might be due to a compensatory 
mechanism to handle a higher availability/load of lipids in the extremely obese cells. 
Moreover, PDK4 is an important factor in switching oxidation towards FAs [223] and is 
also observed to be a PPARδ target gene [310, 312, 314, 316], also in human muscle cells 
[315]. EPA/LA/PA/OA/EPS treatment upregulated PDK4 mRNA expression in 
comparison with BSA treatment, and PA tended to upregulate PDK4 mRNA expression 
compared to OA (Paper I, II and IV). This indicates a PPARδ effect that leads to more 
FA oxidation; however PA might be more potent than OA. PA’s upregulation of this gene 
might explain the higher FA oxidation in comparison with OA; however it does not explain 
PAs higher incomplete FA oxidation. Though, a study found that palmitoyl-carnitine 
content was higher than oleoyl-carnitine in rat myotubes [247], indicating a higher PA 
uptake into the mitochondria than OA. A higher PA than OA oxidation might therefore be 
due to PA-upregulated PDK4 and/or a CPT1 preference for PA. The LXR agonist also 
increased OA oxidation, and increased glucose and OA oxidation in combination with 
EPA (Paper I), in accordance with earlier observations [338, 339]. EPS and EPA+LXR 
agonist in combination were observed to increase glucose oxidation in concert with 
improved insulin sensitivity (Paper I, IV). However, the explanation behind the regulation 
of complete and incomplete FA oxidation by dietary FAs, extreme obesity and exercise 
needs further elaboration.  
Metabolic flexibility was reduced in association with insulin resistance and T2D [281-
284] and in obese individuals [281] in vivo. Definitions of metabolic parameters used in 
vitro are presented in Paper I and III. EPA increased suppressibility, substrate-regulated 
flexibility and adaptability compared to OA, suggesting a beneficial response on substrate 
utilization by EPA in myotubes (Paper I). This beneficial effect might be caused by 
increased lipid storage, or though their role as precursors of eicosanoids [78]. PUFAs are 
perhaps better agonist of PPARs than other FAs [309]. However no increase inn flexibility 
parameters with PPARδ agonist was found and LA (ω-6, PUFA) did not increase these 
parametres (Paper I). Furthermore, adaptability was lower in diabetic compared to non-
diabetic myotubes (Paper III) that might be due to impairment in diabetic muscle 
mitochondria to exchange substrate on demand. However, PA, LA and EPA-treated cells 
had a higher adaptability compared to BSA/OA-treated myotubes, indicating a general FA 
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effect, perhaps via PPAR or upregulation of genes involved in FA oxidation (Paper I). The 
extremely obese myotubes showed however a lower suppressibility than the lean myotubes 
and this might be a consequence of high FA oxidation and thus high pressure on the 
mitochondria (Paper III). The LXR agonist counteracted EPA’s effect on suppressibility 
and adaptability (Paper I), perhaps due to PPAR’s ability to act as an LXR antagonist [299, 
300]. Furthermore, the new parameter, substrate-regulated flexibility tended to be lower in 
diabetics compared to non-diabetics (Paper III), and we conclude that the new flexibility 
parameter can be used in this context.  
EPS seemed to increase the protein level of type I fiber marker (MYH7) in concert with 
increased FA oxidation, as has previously been found after chronic exercise or in 
endurance-trained athletes compared to untrained subjects ([107, 167, 348], Paper IV, 
Erratum IV). EPA treatment did not influence complete FA oxidation, but the results 
revealed that EPA downregulated mRNA expression of markers for type II fibers (MYH1 
and MYH2), compared to BSA treatment (Appendix I). The higher protein expression of 
marker for type I fiber after EPS and lower type II fiber expression after EPA treatment 
corresponded with a tendency towards higher IMCL observed, and higher insulin 
sensitivity after EPS (Paper I and IV). These effects may also be attributed to PPAR, 
since PPARδ is found in association with higher expression of type I fibers [440], and 
PGC-1α overexpression in human myotubes did result in a decreased expression of fiber 
type IIa marker (MYH2) [326] and is proposed as involved in fiber switch. In contrast, 
microarray results showed that PA upregulated fiber type IIx marker (MYH1) compared 
with OA in myotubes (data submitted to Gene expression omnibus (GSEE18589)), as 
found in insulin resistant or obese muscle [272, 277, 278]. Surprisingly, myotubes from 
lean, extremely obese non-diabetics and diabetics showed similar protein expression of 
marker for type I fibers (MYH7, Paper III). 
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Insulin resistance 
Acute treatment with IL-6 has shown to increase both insulin-stimulated and basal glucose 
uptake in rat muscle cells [364]. EPS tended to upregulate, while EPA upregulated IL-6 
mRNA expression (Paper I and IV). IL-6 is a secretory protein and has also been shown 
to activate AMPK [363, 364, 443] and exercise-induced effects are proposed to be 
dependent on AMPK [87, 96, 116, 345, 346](see Figure 8 and 9). Preliminary experiments 
showed that phosphorylated AMPK might be lower in extremely obese myotubes than in 
lean (preliminary data from our lab, N=3, p=0.16), indicating a beneficial effect of its 
activation. An upregulation of IL-6 and subsequently activation of AMPK might therefore 
explain increased complete FA oxidation after EPS and increased incomplete oxidation 
after EPA (see Figure 9) and might also indicate a role for AMPK for increased lipid 
accumulation after EPA/EPS treatments. 
A reduced insulin-stimulated glucose uptake and tendency towards reduced insulin 
signaling (phosphorylation of Akt) was observed in myotubes established from T2D 
subjects (Paper III). A hypothesis for development of insulin resistant muscle was first, a 
lower lipid accumulation and higher lipolysis without an increase in FA oxidation produce 
more lipotoxic intermediates that may interfere with insulin signaling pathway (at p-Akt or 
above). Second, a blunted insulin effect on mitochondrial biogenesis result in lower 
mitochondrial content. Third, mitochondrial content has previously been correlated with 
metabolic flexibility [444], and result in adaptability and substrate-regulated flexibility 
reduction (Paper III). Furthermore, a study has shown improved insulin sensitivity after 
preincubation with EPA in human skeletal muscle cells [438]. However, we did not 
observe a higher insulin-stimulated glucose uptake, insulin signaling (phosphorylation of 
Akt) or glycogen synthesis after EPA treatment in lean myotubes. On the other hand, the 
effect of the LXR agonist on basal glucose uptake was higher with co-incubation with EPA 
than the other FAs alone (Paper I), in accordance with previous findings in myotubes [338, 
339], indicating a beneficial effect of LXRs agonist and EPA in combination. Moreover, 
exercise is well known to improve glucose metabolism [87, 96, 167, 289, 340, 341] and 
EPS increased the insulin-stimulated glucose uptake in myotubes. However, GLUT1 and 
GLUT4 mRNA expression were similar (Paper IV), indicating an increased translocation 
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rather than upregulation of GLUTs (see Figure 8). In addition, the insulin effect on glucose 
uptake and Akt phosphorylation was unaffected by EPS (Paper IV), supporting the 
hypothesis of distinct pathways of exercise- and insulin-induced GLUT4 translocation. The 
effects resemble changes observed in vivo during exercise [289, 340, 341] and we conclude 
that EPS may be used as an in vitro model for exercise.  
 
 
Final considerations 
Finally, it should be noted that the myotubes used in this thesis were from donors of 
different origin, age, gender, physical activity level and the donors might have different 
metabolic disorders. In the case of the studies with myotubes from lean, healthy donors this 
contribution may not be as severe. However, fasting plasma glucose concentrations of the 
extremely obese donors correlated inversely with insulin-stimulated glucose uptake in the 
myotubes (Paper III). Moreover, TAG values, BMI and blood pressure were higher and 
HDL lower in extremely obese donors in comparison with lean donors that may also have 
“left a print” in the myotubes and we observed that the BMI of the donors correlated with 
the mitochondrial staining in their corresponding myotubes (Paper III). Thus, the genetics 
or epigenetics within the donors does influence the behavior of the myotubes. 
The results presented in this thesis, from extremely obese diabetic myotubes and 
EPS/FA-treated skeletal muscle cells, suggest a favorable role of a higher capacity for 
intramyocellular lipid accumulation. This promotes increased metabolic flexibility with 
improved insulin sensitivity and glucose metabolism in human skeletal muscle. Figure 14 
presents the working model of this discussion. 
 
63 
 
 
Figure 14. Our working model. In the insulin resistant state, a low intramyocellular lipid accumulation, high 
lipolysis rate and low mitochondrial content is present. In a non-diabetic state, the mitochondrial content and 
lipid accumulation is higher, while lipolysis is lower and insulin sensitivity improved (Paper III). In “trained” 
(after EPS) cells or the athlete state, lipid accumulation, mitochondrial content, fiber type I marker expression 
and insulin sensitivity is higher to meet the increased energy demand created in these muscles (Paper IV). 
However, there are also evidence not explored in this thesis that lipolysis also is higher in athlete/exercised 
muscle [107, 186, 197, 199, 200], perhaps via AMPK activation [87, 96, 116]. EPA (ω-3 fatty acid) and to 
some extent OA (monounsaturated fatty acid), and LXR agonist treatments contributed positively to this 
(Paper I), while PA (saturated fatty acid) (Paper II), obesity and inactivity contributed negatively. 
Furthermore, EPA downregulated marker expression for fiber type II, while PA upregulated marker for fiber 
type IIx. 
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Future studies 
To further clarify the problems in this thesis it would in future studies be of value to 
examine:  
 Regulation of lipases and PLINs expressions, translocations, post-translational 
modifications, isoforms and presence of co-factors or inhibitors.  
 The possible beneficial effect of increasing lipid accumulation (or decreasing 
lipolysis) in myotubes from obese and diabetic donors.  
 Measure lipotoxic intermediates in relation to interference with insulin 
signaling and lipid accumulation (or lipolysis).  
 Metabolic flexibility parameters in EPS- treated cells in obese and diabetic 
myotubes, and to further study the beneficial effect of EPA.  
 Regulation of GLUT4 translocation and expression in relation to the separate 
effects of EPS and insulin on glucose uptake.  
 The role of CD36 versus GLUT4-containing vesicles, translocation and insulin 
response in the interplay between fatty acid handling and impaired glucose 
metabolism. 
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Appendix I 
 
 
 
 
 
Table A-1. Genes involved in pathways regulated by EPA, OA, PA or LA related to BSA. Myotubes were 
incubated with fatty acids (100 μM) for 24 h and then harvested for RNA isolation. Gene expression was 
measured by Affymetrix human NuGO GeneChip arrays. Genes with q-value < 0.2 (that is, log (q) > 0.7) were 
considered significantly regulated and fold change (FC) is presented. ADFP/PLIN2, adipose differentiation-
related protein/perlipin 2; EPA, eicosapentaenoic acid; OA, oleic acid; PA, palmitic acid; LA, linoleic acid.  
 Fatty acid-regulated genes, related to BSA, q < 0.2 
EPA 
Upregulated 
Gene name EntrezID Mean FC q-value Description 
ADFP 123 2,676775 5,43E-06 adipose differentiation-related protein 
ANGPTL4 51129 3,448598 5,71E-05 angiopoietin-like 4 
PDK4 5166 4,577311 0,000236 pyruvate dehydrogenase kinase, isozyme 4 
CAT 847 1,589811 0,001275 catalase 
KLF11 8462 1,467846 0,01299 Kruppel-like factor 11 
ACADVL 37 1,439108 0,018239 acyl-Coenzyme A dehydrogenase, very long chain 
IMPA2 3613 1,484835 0,018239 inositol(myo)-1(or 4)-monophosphatase 2 
SPOCD1 90853 1,596004 0,018239 SPOC domain containing 1 
FOSL1 8061 1,566343 0,018239 FOS-like antigen 1 
SLC25A20 788 1,394179 0,018239 solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 
CXCL2 2920 1,618288 0,019173 chemokine (C-X-C motif) ligand 2 
NAMPT 10135 1,527298 0,025021 nicotinamide phosphoribosyltransferase 
ABCC3 8714 1,476156 0,044788 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 
ECH1 1891 1,508397 0,057607 enoyl Coenzyme A hydratase 1, peroxisomal 
OSR1 130497 1,40961 0,057607 odd-skipped related 1 (Drosophila) 
IL6 3569 1,544659 0,068279 interleukin 6 (interferon, beta 2) 
SLC6A15 55117 1,715871 0,068279 solute carrier family 6, member 15 
F2RL1 2150 1,633449 0,068279 coagulation factor II (thrombin) receptor-like 1 
FLCN 201163 1,442192 0,091093 folliculin 
C2orf18 54978 1,3535 0,092997 chromosome 2 open reading frame 18 
RALA 5898 1,267809 0,098387 v-ral simian leukemia viral oncogene homolog A (ras related) 
HES2 54626 1,389738 0,098387 hairy and enhancer of split 2 (Drosophila) 
MT1X 4501 1,699545 0,099041 metallothionein 1X 
HMOX1 3162 1,606951 0,099041 heme oxygenase (decycling) 1 
SLC25A34 284723 1,59241 0,122649 solute carrier family 25, member 34 
SQLE 6713 1,316659 0,129442 squalene epoxidase 
UPP1 7378 1,348286 0,136419 uridine phosphorylase 1 
C5orf32 84418 1,297268 0,136419 chromosome 5 open reading frame 32 
MT1F 4494 1,577383 0,136809 metallothionein 1F 
C10orf12 26148 1,295043 0,148916 chromosome 10 open reading frame 12 
ACACB 32 1,408865 0,148916 acetyl-Coenzyme A carboxylase beta 
PCIF1 63935 1,382618 0,150552 PDX1 C-terminal inhibiting factor 1 
LIF 3976 1,379168 0,154335 leukemia inhibitory factor (cholinergic differentiation factor) 
PPP1R15A 23645 1,230676 0,156188 protein phosphatase 1, regulatory (inhibitor) subunit 15A 
TNFAIP3 7128 1,290405 0,17038 tumor necrosis factor, alpha-induced protein 3 
DLEC1 9940 1,285832 0,173634 deleted in lung and esophageal cancer 1 
CTSH 1512 1,226963 0,173634 cathepsin H 
TRIM47 91107 1,256264 0,174838 tripartite motif-containing 47 
TAC3 6866 1,350827 0,174838 tachykinin 3 
SKAP2 8935 1,216654 0,198085 src kinase associated phosphoprotein 2 
Downregulated 
STON1 11037 -1,50835 0,010368 stonin 1 
MAMDC2 256691 -1,49071 0,018239 MAM domain containing 2 
ADRB2 154 -1,74902 0,018239 adrenergic, beta-2-, receptor, surface 
ABCA1 19 -2,06969 0,018239 ATP-binding cassette, sub-family A (ABC1), member 1 
C5 727 -1,57227 0,018239 complement component 5 
RNF144B 255488 -1,70537 0,018239 ring finger 144B 
TMEM178 130733 -1,75903 0,018239 transmembrane protein 178 
MYH1 4619 -1,72823 0,018895 myosin, heavy chain 1, skeletal muscle, adult 
HSPA2 3306 -1,80678 0,019173 heat shock 70kDa protein 2 
GDF6 392255 -1,55371 0,019173 growth differentiation factor 6 
FRY 10129 -1,59231 0,019173 furry homolog (Drosophila) 
VASH1 22846 -1,5968 0,025021 vasohibin 1 
GPR126 57211 -1,76963 0,025021 G protein-coupled receptor 126 
EBF3 253738 -1,40214 0,025981 early B-cell factor 3 
SLC39A10 57181 -1,4292 0,043553 solute carrier family 39 (zinc transporter), member 10 
B3GALT2 8707 -1,52979 0,057607 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2 
ATP1B4 23439 -1,52371 0,057607 ATPase, (Na+)/K+ transporting, beta 4 polypeptide 
XG 7499 -1,36217 0,061487 Xg blood group 
TXNIP 10628 -1,27888 0,067245 thioredoxin interacting protein 
MTMR4 9110 -1,42535 0,067245 myotubularin related protein 4 
ALDH1A1 216 -1,37716 0,067245 aldehyde dehydrogenase 1 family, member A1 
SLITRK4 139065 -1,51582 0,067945 SLIT and NTRK-like family, member 4 
WDR42A 50717 -1,47639 0,068279 WD repeat domain 42A 
NFYB 4801 -1,39585 0,068279 nuclear transcription factor Y, beta 
EFNB2 1948 -1,45402 0,068279 ephrin-B2 
TLE4 7091 -1,34697 0,075208 transducin-like enhancer of split 4 (E(sp1) homolog, Drosophila) 
FBXW7 55294 -1,41743 0,07862 F-box and WD repeat domain containing 7 
ERCC5 2073 -1,35139 0,07862 excision repair cross-complementing rodent repair deficiency, complementation group 5 
ABCA8 10351 -1,37673 0,092997 ATP-binding cassette, sub-family A (ABC1), member 8 
SLC44A1 23446 -1,32982 0,098387 solute carrier family 44, member 1 
LPGAT1 9926 -1,36158 0,098387 lysophosphatidylglycerol acyltransferase 1 
ADARB1 104 -1,42415 0,098387 adenosine deaminase, RNA-specific, B1 (RED1 homolog rat) 
MYH2 4620 -1,45356 0,099041 myosin, heavy chain 2, skeletal muscle, adult 
C15orf52 388115 -1,318 0,103494 chromosome 15 open reading frame 52 
LYPD6B 130576 -1,36324 0,107867 LY6/PLAUR domain containing 6B 
DNAJB6 10049 -1,28972 0,108609 DnaJ (Hsp40) homolog, subfamily B, member 6 
CPM 1368 -1,51664 0,108609 carboxypeptidase M 
LRRC1 55227 -1,36114 0,108609 leucine rich repeat containing 1 
TP53INP2 58476 -1,3418 0,108609 tumor protein p53 inducible nuclear protein 2 
RCAN2 10231 -1,36619 0,108609 regulator of calcineurin 2 
AMPH 273 -1,51101 0,108609 amphiphysin 
ABAT 18 -1,45773 0,110124 4-aminobutyrate aminotransferase 
PLK2 10769 -1,3957 0,110674 polo-like kinase 2 (Drosophila) 
SORBS2 8470 -1,2938 0,119243 sorbin and SH3 domain containing 2 
WDR5 11091 -1,29399 0,119243 WD repeat domain 5 
OSAP 84709 -1,40281 0,119243 ovary-specific acidic protein 
C1orf83 127428 -1,3601 0,119243 chromosome 1 open reading frame 83 
ADAMTS5 11096 -1,43301 0,119243 ADAM metallopeptidase with thrombospondin type 1 motif, 5 
PRR15 222171 -1,33503 0,119243 proline rich 15 
MFAP3L 9848 -1,32287 0,119243 microfibrillar-associated protein 3-like 
PLA2G4A 5321 -1,40289 0,122287 phospholipase A2, group IVA (cytosolic, calcium-dependent) 
CLTB 1212 -1,25697 0,122287 clathrin, light chain (Lcb) 
MTUS1 57509 -1,37696 0,122385 mitochondrial tumor suppressor 1 
C10orf54 64115 -1,29827 0,122605 chromosome 10 open reading frame 54 
CAMK2N1 55450 -1,24378 0,122649 calcium/calmodulin-dependent protein kinase II inhibitor 1 
DAPK1 1612 -1,36291 0,122649 death-associated protein kinase 1 
ANGPT1 284 -1,49822 0,122649 angiopoietin 1 
KIAA0430 9665 -1,27518 0,122649 KIAA0430 
TEAD1 7003 -1,22736 0,12933 TEA domain family member 1 (SV40 transcriptional enhancer factor) 
CCDC136 64753 -1,42117 0,136419 coiled-coil domain containing 136 
TEK 7010 -1,43594 0,136419 TEK tyrosine kinase, endothelial 
SH3D19 152503 -1,28666 0,136419 SH3 domain containing 19 
GYG2 8908 -1,40894 0,136419 glycogenin 2 
LOC28402
3 284023 -1,35869 0,136419 hypothetical protein LOC284023 
IVNS1ABP 10625 -1,34122 0,148102 influenza virus NS1A binding protein 
SLC6A6 6533 -1,28415 0,148916 solute carrier family 6 (neurotransmitter transporter, taurine), member 6 
PPFIBP2 8495 -1,44836 0,148916 PTPRF interacting protein, binding protein 2 (liprin beta 2) 
FOLR1 2348 -1,27793 0,148916 folate receptor 1 (adult) 
MAP2 4133 -1,37278 0,150552 microtubule-associated protein 2 
JSRP1 126306 -1,29924 0,156188 junctional sarcoplasmic reticulum protein 1 
TNNT2 7139 -1,23634 0,156188 troponin T type 2 (cardiac) 
VGLL2 245806 -1,28626 0,160229 vestigial like 2 (Drosophila) 
LBH 81606 -1,26332 0,16476 limb bud and heart development homolog (mouse) 
PRTFDC1 56952 -1,39798 0,165333 phosphoribosyl transferase domain containing 1 
LOC10012
9762 
10012976
2 -1,23741 0,165806 similar to KIAA0367 
FBXO32 114907 -1,2737 0,165806 F-box protein 32 
MEIS1 4211 -1,31548 0,165806 Meis homeobox 1 
PTCH1 5727 -1,53641 0,166938 patched homolog 1 (Drosophila) 
CCL13 6357 -1,38921 0,166938 chemokine (C-C motif) ligand 13 
TMEM119 338773 -1,25072 0,166938 transmembrane protein 119 
HEYL 26508 -1,47755 0,166938 hairy/enhancer-of-split related with YRPW motif-like 
SLC4A4 8671 -1,41778 0,166938 solute carrier family 4, sodium bicarbonate cotransporter, member 4 
OSR2 116039 -1,35493 0,17038 odd-skipped related 2 (Drosophila) 
EFHD1 80303 -1,2711 0,17038 EF-hand domain family, member D1 
ACAD8 27034 -1,26313 0,172488 acyl-Coenzyme A dehydrogenase family, member 8 
MCCC1 56922 -1,2733 0,173634 methylcrotonoyl-Coenzyme A carboxylase 1 (alpha) 
OTUD1 220213 -1,26246 0,173634 OTU domain containing 1 
STARD13 90627 -1,26388 0,173634 StAR-related lipid transfer (START) domain containing 13 
VIT 5212 -1,36047 0,173634 vitrin 
TNFSF4 7292 -1,37819 0,173634 tumor necrosis factor (ligand) superfamily, member 4 
SPTBN1 6711 -1,23149 0,173634 spectrin, beta, non-erythrocytic 1 
CDK5RAP
3 80279 -1,23843 0,174838 CDK5 regulatory subunit associated protein 3 
SLC46A3 283537 -1,45166 0,174838 solute carrier family 46, member 3 
REEP1 65055 -1,27231 0,174838 receptor accessory protein 1 
C8orf58 541565 -1,26186 0,174838 chromosome 8 open reading frame 58 
ITGA6 3655 -1,20492 0,174838 integrin, alpha 6 
NEDD4L 23327 -1,37693 0,174838 neural precursor cell expressed, developmentally down-regulated 4-like 
GAS1 2619 -1,26959 0,174838 growth arrest-specific 1 
C10orf10 11067 -1,33307 0,174838 chromosome 10 open reading frame 10 
EIF4A2 1974 -1,1799 0,174838 eukaryotic translation initiation factor 4A, isoform 2 
PLCB4 5332 -1,45635 0,174838 phospholipase C, beta 4 
LIMCH1 22998 -1,2803 0,175789 LIM and calponin homology domains 1 
MACF1 23499 -1,24536 0,178125 microtubule-actin crosslinking factor 1 
SDPR 8436 -1,46712 0,18401 serum deprivation response (phosphatidylserine binding protein) 
MYF5 4617 -1,55998 0,18401 myogenic factor 5 
MYOM1 8736 -1,32107 0,18401 myomesin 1, 185kDa 
DTX4 23220 -1,4527 0,185602 deltex 4 homolog (Drosophila) 
WEE1 7465 -1,34847 0,185602 WEE1 homolog (S. pombe) 
RNF38 152006 -1,37914 0,186522 ring finger protein 38 
FBLN5 10516 -1,212 0,190924 fibulin 5 
CEP63 80254 -1,24088 0,199118 centrosomal protein 63kDa 
PAPPA 5069 -1,31747 0,199246 pregnancy-associated plasma protein A, pappalysin 1 
OA 
Upregulated 
ADFP 123 2,272462 4,46E-05 adipose differentiation-related protein 
PDK4 5166 5,971675 4,46E-05 pyruvate dehydrogenase kinase, isozyme 4 
ANGPTL4 51129 2,717409 0,000639 angiopoietin-like 4 
CAT 847 1,525803 0,004108 catalase 
IMPA2 3613 1,475581 0,034696 inositol(myo)-1(or 4)-monophosphatase 2 
ACADVL 37 1,416289 0,034696 acyl-Coenzyme A dehydrogenase, very long chain 
ECH1 1891 1,631235 0,036468 enoyl Coenzyme A hydratase 1, peroxisomal 
SNN 8303 1,448111 0,048225 stannin 
SLC25A34 284723 1,867299 0,053586 solute carrier family 25, member 34 
OSR1 130497 1,426541 0,081994 odd-skipped related 1 (Drosophila) 
CXCL2 2920 1,511862 0,098956 chemokine (C-X-C motif) ligand 2 
SPOCD1 90853 1,444781 0,11201 SPOC domain containing 1 
KLF11 8462 1,310076 0,122705 Kruppel-like factor 11 
SLC25A20 788 1,295436 0,128156 solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 
NEURL2 140825 1,506356 0,128156 neuralized homolog 2 (Drosophila) 
FOSL1 8061 1,376992 0,193161 FOS-like antigen 1 
Downregulated 
INSIG1 3638 -1,49267 0,030974 insulin induced gene 1 
SCD 6319 -1,59416 0,034696 stearoyl-CoA desaturase (delta-9-desaturase) 
LOC10013
3348 
100133
188 -1,82308 0,048225 hypothetical protein LOC100133348 
HMGCS1 3157 -1,69 0,048225 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble) 
LPGAT1 9926 -1,46522 0,053586 lysophosphatidylglycerol acyltransferase 1 
FADS2 9415 -1,4497 0,064072 fatty acid desaturase 2 
SC4MOL 6307 -1,49538 0,081994 sterol-C4-methyl oxidase-like 
ACAT2 39 -1,76328 0,091148 acetyl-Coenzyme A acetyltransferase 2 
MVD 4597 -1,59899 0,094947 mevalonate (diphospho) decarboxylase 
PRR15 222171 -1,40285 0,109537 proline rich 15 
GDF6 392255 -1,43564 0,122705 growth differentiation factor 6 
SLC6A6 6533 -1,34866 0,128156 solute carrier family 6 (neurotransmitter transporter, taurine), member 6 
XG 7499 -1,33879 0,128156 Xg blood group 
TMEM178 130733 -1,54384 0,14222 transmembrane protein 178 
LOC10012
9762 
100129
762 -1,28934 0,150972 similar to KIAA0367 
RNF144B 255488 -1,48682 0,170369 ring finger 144B 
NQO1 1728 -1,29801 0,170369 NAD(P)H dehydrogenase, quinone 1 
IDI1 3422 -1,45248 0,170369 isopentenyl-diphosphate delta isomerase 1 
FDPS 2224 -1,43701 0,180673 
farnesyl diphosphate synthase (farnesyl pyrophosphate 
synthetase, 
dimethylallyltranstransferase, geranyltranstransferase) 
SCML2 10389 -1,46026 0,199695 sex comb on midleg-like 2 (Drosophila) 
PA 
Upregulated 
PDK4 5166 4,932484 0,000453 pyruvate dehydrogenase kinase, isozyme 4 
ADFP 123 1,90402 0,000919 adipose differentiation-related protein 
CAT 847 1,607211 0,001519 catalase 
ANGPTL4 51129 2,418763 0,002532 angiopoietin-like 4 
DHRS3 9249 1,745998 0,01238 dehydrogenase/reductase (SDR family) member 3 
ECH1 1891 1,687221 0,030494 enoyl Coenzyme A hydratase 1, peroxisomal 
ACADVL 37 1,39974 0,064705 acyl-Coenzyme A dehydrogenase, very long chain 
SLC25A20 788 1,342265 0,139183 solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 
ASPA 443 1,731415 0,139183 aspartoacylase (Canavan disease) 
CD36 948 1,517799 0,192649 CD36 molecule (thrombospondin receptor) 
IMPA2 3613 1,373707 0,193087 inositol(myo)-1(or 4)-monophosphatase 2 
LA 
Upregulated 
ADFP 123 2,074636 0,000356 adipose differentiation-related protein 
PDK4 5166 4,408119 0,000566 pyruvate dehydrogenase kinase, isozyme 4 
ANGPTL4 51129 2,419887 0,003266 angiopoietin-like 4 
CAT 847 1,508029 0,00635 catalase 
CXCL2 2920 1,80077 0,010969 chemokine (C-X-C motif) ligand 2 
IMPA2 3613 1,550102 0,012036 inositol(myo)-1(or 4)-monophosphatase 2 
ECH1 1891 1,572001 0,10183 enoyl Coenzyme A hydratase 1, peroxisomal 
ACADVL 37 1,341482 0,141395 acyl-Coenzyme A dehydrogenase, very long chain 
SCG2 7857 1,431784 0,143893 secretogranin II (chromogranin C) 
SLC25A34 284723 1,76774 0,143893 solute carrier family 25, member 34 
IL8 3576 1,612842 0,169838 interleukin 8 
CXCL1 2919 1,494875 0,169838 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 
RNF145 153830 1,522137 0,169838 ring finger protein 145 
FOSL1 8061 1,415052 0,183635 FOS-like antigen 1 
SLC25A20 788 1,296048 0,183635 solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 
KLF11 8462 1,286423 0,186328 Kruppel-like factor 11 
IRF7 3665 1,375087 0,186328 interferon regulatory factor 7 
NAMPT 10135 1,392262 0,19171 nicotinamide phosphoribosyltransferase 
SLC6A15 55117 1,632492 0,19171 solute carrier family 6, member 15 
GDF15 9518 1,34191 0,193354 growth differentiation factor 15 
Downregulated 
SCD 6319 -1,67326 0,014287 stearoyl-CoA desaturase (delta-9-desaturase) 
GDF6 392255 -1,49077 0,128727 growth differentiation factor 6 
FADS2 9415 -1,43939 0,128727 fatty acid desaturase 2 
LOC10013
3348 
100133
188 -1,73345 0,133036 hypothetical protein LOC100133348 
C5 727 -1,43627 0,169838 complement component 5 
ACAT2 39 -1,6866 0,183635 acetyl-Coenzyme A acetyltransferase 2 
VASH1 22846 -1,46466 0,186328 vasohibin 1 
WDR5 11091 -1,32265 0,186328 WD repeat domain 5 
MAMDC2 256691 -1,33878 0,186328 MAM domain containing 2 
FDPS 2224 -1,45774 0,186328 
farnesyl diphosphate synthase (farnesyl pyrophosphate 
synthetase, 
dimethylallyltranstransferase, geranyltranstransferase) 
ANLN 54443 -1,52072 0,186328 anillin, actin binding protein 
SLC6A6 6533 -1,33022 0,186328 solute carrier family 6 (neurotransmitter transporter, taurine), member 6 
POU2F1 5451 -1,40541 0,186328 POU class 2 homeobox 1 
TEAD1 7003 -1,25282 0,186328 TEA domain family member 1 (SV40 transcriptional enhancer factor) 
RNF144B 255488 -1,48955 0,186328 ring finger 144B 
TTN 7273 -1,89547 0,186328 titin 
PCYT2 5833 -1,32698 0,186328 phosphate cytidylyltransferase 2, ethanolamine 
KRT34 3885 -1,49517 0,186328 keratin 34 
NEDD4L 23327 -1,46331 0,19171 neural precursor cell expressed, developmentally down-regulated 4-like 
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Electrical Pulse Stimulation of Cultured Human Skeletal
Muscle Cells as an In Vitro Model of Exercise
Natasˇa Nikolic´1*, Siril Skaret Bakke1, Eili Tranheim Kase1, Ida Rudberg1,2, Ingeborg Flo Halle1, Arild C.
Rustan1, G. Hege Thoresen1, Vigdis Aas2
1Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway, 2 Faculty of Health Sciences, Oslo and Akershus University College of
Applied Sciences, Oslo, Norway
Abstract
Background and Aims: Physical exercise leads to substantial adaptive responses in skeletal muscles and plays a central role
in a healthy life style. Since exercise induces major systemic responses, underlying cellular mechanisms are difficult to study
in vivo. It was therefore desirable to develop an in vitro model that would resemble training in cultured human myotubes.
Methods: Electrical pulse stimulation (EPS) was applied to adherent human myotubes. Cellular contents of ATP,
phosphocreatine (PCr) and lactate were determined. Glucose and oleic acid metabolism were studied using radio-labeled
substrates, and gene expression was analyzed using real-time RT-PCR. Mitochondrial content and function were measured
by live imaging and determination of citrate synthase activity, respectively. Protein expression was assessed by
electrophoresis and immunoblotting.
Results: High-frequency, acute EPS increased deoxyglucose uptake and lactate production, while cell contents of both ATP
and PCr decreased. Chronic, low-frequency EPS increased oxidative capacity of cultured myotubes by increasing glucose
metabolism (uptake and oxidation) and complete fatty acid oxidation. mRNA expression level of pyruvate dehydrogenase
complex 4 (PDK4) was significantly increased in EPS-treated cells, while mRNA expressions of interleukin 6 (IL-6), cytochrome
C and carnitin palmitoyl transferase b (CPT1b) also tended to increase. Intensity of MitoTrackerHRed FM was doubled after
48 h of chronic, low-frequency EPS. Protein expression of a slow fiber type marker (MHCI) was increased in EPS-treated cells.
Conclusions: Our results imply that in vitro EPS (acute, high-frequent as well as chronic, low-frequent) of human myotubes
may be used to study effects of exercise.
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Introduction
Physical training leads to extensive adaptations in skeletal
muscles [1-4]. Regular physical activity plays central role in both
prevention and improvement of many chronic diseases, improve-
ment of life-style and increased life expectancy [2]. However,
molecular mechanisms underlying these adaptations are still
poorly understood, emphasizing the requirement for a cell culture
model resembling training ex vivo.
Motor neuron activation of muscle fibres can be replaced by
electrical pulse stimulation (EPS) of differentiated skeletal muscle
cells (myotubes) in culture [5,6]. Metabolic and genetic adapta-
tions caused by EPS in vitro have previously been described in
murine C2C12 cells [7-9], in L6 cells [10] and in primary rat
skeletal muscle cells [11]. In vivo, immediate effects of EPS, such as
activation of glucose uptake and glycogenolysis [12] can be clearly
distinguished from more profound changes in the metabolic and
transcriptional phenotypes of muscles occurring as a result of
chronically increased contractile activity evoked by chronic, low-
frequency EPS [12]. Likewise, acute changes in skeletal muscle
after a single bout of exercise in vivo differ considerably from those
observed after regular training, which, obviously, confers for the
most of the beneficial health effects of exercise in vivo [2,13].
Adaptations of metabolic properties in skeletal muscles after
exercise are reflected by both increased mitochondrial content
[14,15] and improved oxidative capacity [4,16,17]. Several
signalling pathways have been proposed to be involved in the
stimulation of mitochondrial biogenesis in a contracting muscle
[18-20]. Exercise has also been shown to enhance both lipid
synthesis and lipid oxidation [20-23]. As a consequence of these
metabolic adaptations, trained muscle takes more of its required
energy from lipids and less from carbohydrate compared to
untrained muscle during submaximal work (i.e. work performed
below the maximal oxygen utilization capacity) [24]. In addition to
fatty acids, trained fibers import and use more glucose than
untrained muscle fibers [25,26]. Glucose transporters 1 and 4
(GLUT1 and GLUT4) are the major glucose transporters in the
cell membrane of skeletal muscle cells [27], and regular physical
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activity improves the ability of insulin to stimulate the uptake of
glucose at rest [28-30].
Plasticity of skeletal muscles in response to endurance exercise
extends beyond the metabolic changes. In human skeletal muscles,
three main muscle fiber types, type I (oxidative, slow twitch), IIa
(intermediate) and IIx (glycolytic, fast twitch), can be delineated
based on histochemical, functional and biochemical properties
[31]. Type I fibers are characterized by higher mitochondrial
content and increased glucose transport compared to type II
fibers, and whole-body insulin-sensitivity has been positively
correlated with the proportion of slow-twitch oxidative fibers in
humans [32]. Conversion from type II to type I muscle phenotype
has been shown in animals [33], but there is little evidence that this
type of transition actually happens in adult humans [15,24].
Chronic, low-frequency EPS in vivo has been shown to lead to the
transformation of fast-twitch glycolytic muscle fibres into slow-type
oxidative fibres [12]. Moreover, skeletal muscle has recently been
identified as an organ that produces and releases several cytokines,
which are termed ‘‘myokines’’, among these are interleukins 6, 8
and 5 (IL-6, IL-8 and IL-5) [34]. It has been demonstrated that
plasma concentration of IL-6 increases during muscular exercise
[35,36], and IL-6 appears to have positive effects on skeletal
muscle glucose metabolism [37,38]. These findings suggest that
also the immune system is affected by physical exercise; however,
the implications this might have on the metabolic responses are
not yet understood.
We have previously reported effects of acute electrical
stimulation on glucose metabolism in cultured human skeletal
muscle cells, both at high and low glucose concentrations [39].
In the past years, reports of several EPS models applied to cultured
skeletal muscle cells have increased in number, suggesting that
there is growing interest in establishing a method that would allow
to study cellular mechanisms of exercise under controlled
conditions in vitro [6-9,11,40]. However, to our knowledge, no
model of EPS has been applied to primary human skeletal muscle
cells. Cell culture systems derived from muscle biopsies have been
used to study glucose and lipid metabolism over the past 30 years.
Differentiated primary human myotubes represent the best
available alternative system to intact human skeletal muscle. They
have the most relevant genetic background to study human disease
as opposed to rodent culture systems, and they also display the
morphological, metabolic and biochemical properties of adult
skeletal muscles [41,42].
In the present study, we aimed to develop an in vitro model of
exercise in cultured human skeletal muscle cells, with main focus
on metabolic effects of chronic, low-frequency EPS. This model
could be used to study adaptive responses of skeletal muscle cells to
different types of contractile activity applied by electrical pulse
stimulation (EPS).
Materials and Methods
Materials
Dulbecco`s modified Eagle`s medium (DMEM-GlutamaxTM),
heat-inactivated fetal calf serum (FCS), penicillin/streptomycin
(P/S) and amphotericin B were purchased from Gibco (Gibco,
Life Technologies Paisley, UK). BSA (Bovine Serum Albumin)
(essentially fatty acid-free), L-carnitine, and Dulbecco’s phosphate-
buffered saline (DPBS; with Mg2+ and Ca2+), oleic acid,
extracellular matrix (ECM) gel and HEPES were obtained from
Sigma (St Louis, MO). Ultroser G was purchased from Ciphergen
(Cergy-Saint-Christophe, France), and insulin (ActrapidH) was
from NovoNordisk (Bagsvaerd, Denmark). [1-14C]oleic acid
(55 mCi/mmol) and D-[14C(U)]glucose (5 mCi/mmol) were from
NEN Radiochemicals, PerkinElmer (Boston, MA). [3H]deoxyglu-
cose (10 Ci/mmol) was from American Radiolabeled Chemicals
Inc. (St. Louis, MO). Ecoscint A scintillation solution was from
National diagnostics (Hessle, England, UK). Glass bottom plates
were from MatTek (Ashland, MA). Protein assay reagens was
purchased from BioRad (Copenhagen, Denmark). Phospho-Akt
(Ser473) and Akt antibodies were from Cell Signaling Technology
(Beverly, MA), OXPHOS human cocktail antibodies were from
MitoSciences (Eugene, OR) and Anti-Myosin, slow muscle
(MAB1628) was from Millipore (Billerica, MA). MitoTrackerHRed
FM and Hoechst 33258 were obtained from Molecular Probes,
Invitrogen (Carlsbad, CA). NuPAGEH 4–12% (w/v) Bis-Tris Gel,
1 mm612 well was from Invitrogen (Carlsbad, CA). Citrate
Synthase Activity Assay Kit was from Sigma-AldrichH (St. Louis,
MO). Cytotoxicity Detection Kit Plus (LDH) was from Roche
Applied Science, Mannheim, Germany. The primers for TaqMan
Real Time PCR were provided by Invitrogen (Carlsbad, CA).
SYBR green and TaqMan reverse transcription kit reagents were
obtained from Applied Biosystems (Warrington, UK). Agilent
Total RNA isolation Kit was purchased from Agilent Technolo-
gies (Santa Clara, CA). All chemicals used were of standard
commercial high-purity quality.
Ethics statement
The biopsies were obtained with informed written consent and
approval by the National Committee for Research Ethics (Oslo,
Norway). The research performed in this study was approved, as a
part of a larger project, by the National Committee for Research
Ethics (Oslo, Norway).
Human skeletal muscle cell cultures
A cell bank of satellite cells was established from muscle biopsy
samples of the Musculus obliquus internus abdominis of twelve healthy
volunteers (10 females, 2 males), age range 34–70 years (50.969
years), body mass index (BMI) range 19.6–29.7 kg/m2
(23.960.9 kg/m2), fasting glucose range range 4.9–6.9 mM
(5.260.2 mM), and plasma lipids and blood pressure within
normal range. Not all donors were used in each experiment.
Muscle cell cultures free of fibroblasts were established by the
method of Henry et al [42]. Briefly, muscle tissue was dissected in
Ham’s F-10 medium at 4uC and dissociated by three successive
treatments with 0.05% trypsin/EDTA, and satellite cells were
resuspended in skeletal muscle DMEM-GlutamaxTM with 2%
FCS, 2% Ultroser G, 50 U/mL penicillin, 50 mg/mL streptomy-
cin, 1.25 mg/mL amphotericin B, and no added insulin. The cells
were grown on culture wells or flasks coated with extracellular
matrix gel [43]. After 1–2 weeks, at ,80% confluence, growth
medium was replaced by DMEM-GlutamaxTM with 2% FCS,
50 U/mL penicillin, 50 mg/mL streptomycin, 1.25 mg/mL am-
photericin B and 25 pM insulin to induce the differentiation of
myoblasts into multinucleated myotubes. The cells were cultured
in a humidified 5% CO2 atmosphere at 37uC, and medium was
changed every 2–3 days. All myotube cultures were used for
analysis on day 8 or 9 after the onset of differentiation.
Electrical pulse stimulation of muscle cells
Multinucleated myotubes grown in ECM-coated 6-well plates
were stimulated via carbon electrodes either by applying acute,
high-frequency EPS (pulse trains of bipolar pulses 100 Hz for
200 ms given every 5th second, 30 V, for 5–60 min), or by
applying chronic, low-frequency EPS (single, bipolar pulses of
2 ms, with 30 V and 1 Hz continuously for the last 24 or 48 h of
differentiation period). Culturing medium was changed every
12th h during chronic, low-frequency EPS. Electrical pulses were
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generated by a muscle stimulator built at the Electronics Lab,
Institute of Chemistry, University of Oslo.
Contents of ATP, PCr and lactate
The myotubes were preincubated for 1 h (37uC, 5% CO2) with
DMEM-GlutamaxTM. Medium was then changed to fresh
DMEM-GlutamaxTM and acute, high-frequency EPS was applied
for 5–60 min. After stimulation, the cells were immediately placed
on ice, the media were removed, and the cells were washed three
times with ice-cold phosphate-buffered saline (PBS) before being
harvested in 200 mL of ice-cold perchloric acid (3 M). Analyses of
ATP, PCr and lactate contents were performed at the Institute for
Experimental Medical Research, Ulleva˚l University Hospital,
Oslo. The cells were analyzed for ATP and PCr levels with
luminescence spectrometry, and lactate content in cells was
analyzed with fluorescence spectrometry as described by Lowry
et al. [44].
Measurement of lactate dehydrogenase (LDH)
in culture media from myotubes treated with chronic,
low-frequency EPS
Cytotoxic effect of EPS was determined in a colorimetric assay
based on the measurement of lactate dehydrogenase (LDH)
activity in the supernatant with the use of Cytotoxicity Detection
KitPLUS (LDH) (Roche Applied Science, Mannheim, Germany).
Multinucleated myotubes grown in ECM-coated 6-well plates
were stimulated via carbon electrodes by applying chronic, low-
frequency EPS continuously for the last 24 h or 48 h of the
differentiation, and LDH activity in the supernatant was
determined according to the supplier’s protocol. Triton-X-100-
lysed cells were used for determination of maximum values.
Glucose metabolism
Initial experiments with frequency-dependent deoxy-
glucose uptake: The myotubes were starved for 60 min in serum-
free DMEM-GlutamaxTM (5.5 mM glucose) in a 5% CO2
incubator at 37uC. Then, the medium was changed to serum-free
DMEM-GlutamaxTM with [3H]deoxyglucose (1 mCi/mL) +/2
cytochalasin B (20 mM), and acute EPS was applied for the first
15 min of the 60 min deoxyglucose uptake period, using frequen-
cies of 2 to 10 Hz. Deoxyglucose uptake at acute, high-
frequency EPS: The myotubes were starved for 60 min in serum-
free DMEM-GlutamaxTM (5.5 mM glucose) in a 5% CO2
incubator at 37uC. Then, the medium was changed to serum-free
DMEM-GlutamaxTM with [3H]deoxyglucose (1 mCi/mL) +/2
insulin (100 nM) and +/2 cytochalasin B (20 mM), and acute, high-
frequency EPS was applied for 5–60 min. Deoxyglucose uptake
after chronic, low-frequency EPS: Chronic, low-frequency
EPS was applied to myotubes continuously for the last 24–48 h of
the differentiation period. After ended EPS, the myotubes were
starved for 60 min in serum-free DMEM-GlutamaxTM (5.5 mM
glucose) in a 5% CO2 incubator at 37uC, and then exposed to
[3H]deoxyglucose (1 mCi/mL) +/2 insulin (100 nM) and +/2
cytochalasin B (20 mM). Deoxyglucose uptake was measured for
60 min for both acute, high-frequency EPS and chronic, low-
frequency EPS. After ended uptake, the cells were immediately
placed on ice and washed three times with ice-cold PBS, lysed with
0.05 M NaOH, and radioactivity was counted by liquid scintilla-
tion. The protein content of each sample was measured according
to Bradford [45]. Non-carrier-mediated uptake was determined in
the presence of cytochalasin B and subtracted from all presented
values. Glucose oxidation after chronic, low-frequency
EPS: Chronic, low-frequency EPS was applied to myotubes for 24
or 48 h. Then, the myotubes were incubated with glucose-free
DMEM and D-[14C(U)]glucose (2 mCi/mL) (1 mL/well) in a 5%
CO2 incubator at 37uC. After 2 h, 500 mL cell medium was
transferred to airtight flasks, and 300 mL of phenyl ethylamine-
methanol (1:1, v/v) was added with a syringe to a center well
containing a folded filter paper. Subsequently, 100 mL of 1 M
perchloric acid was added to the media through the stopper tops
using a syringe. The flasks were placed for a minimum of 2 h at
room temperature to trap labeled CO2, and radioactivity was
counted by liquid scintillation The protein content of each sample
was measured according to Bradford [45].
Fatty acid metabolism after chronic, low-frequency EPS
After 24–48 h of chronic, low-frequency EPS, the myotubes
were exposed to 1 mL/well of DPBS supplemented with HEPES
(10 mM), NaHCO3 (44 mM), [1-
14C]oleic acid (1 mCi/mL,
0.1 mM), 0.24 mM BSA and 1 mM L-carnitine in a 5% CO2
incubator at 37uC. After 2 h, 500 mL of cell medium was
transferred to airtight flasks, and 300 mL of phenyl ethylamine-
methanol (1:1, v/v) was added with a syringe to a center well
containing a folded filter paper. Subsequently, 100 mL of 1 M
perchloric acid was added to the media through the stopper tops
using a syringe. The flasks were placed for a minimum of 2 h at
room temperature to trap labeled CO2. To measure ß-oxidation
products (acid-soluble metabolites (ASMs)), aliquots of 250 mL of
the cell media were precipitated with 100 mL of 6% BSA and
1 mL of 1 M perchloric acid. After centrifugation (20000 g,
10 min, 4uC, Heraues Fresco21 Centrifuge, Thermo Scientific),
250 mL of the supernatant was counted by liquid scintillation. No-
cell controls were included and subtracted from all presented
values. The cells were placed on ice and washed three times with
ice-cold PBS, lysed with 0.05 M NaOH, and cell-associated (CA)
radioactivity was counted by liquid scintillation to determine the
uptake of oleic acid. The protein content of each sample was
measured according to Bradford [45].
Immunoblotting after chronic, low-frequency EPS
Aliquots of 40 mg cell protein from total cell lysates prepared in
Laemmli buffer were electrophoretically separated on NuPAGEH 4–
12%(w/v) Bis-Tris Gel (Invitrogen) followed by immunoblotting with
antibodies recognizing total Akt kinase [protein kinase B (PKB)], Akt
phosphorylated at Ser478, and protein complexes of the electron
transport chain (OXPHOS human cocktail containing antibodies
against Complex I subunit NDUFB8, Complex II subunit, Complex
III subunit core 2, Complex IV subunit II and ATP synthase subunit
alpha) and Myosin, slow muscle (MHCI). Immunoreactive bands
were visualized with enhanced chemiluminescence and quantified
with Gel-Pro Analyzer (version 2.0) software.
Staining and live imaging of mitochondria and enzyme
activity assay after chronic, low-frequency EPS
Myotubes were cultured in ECM-coated 6-well glass bottom
plates. Chronic, low-frequency EPS was applied to cultured
myotubes for the last 48 h of the differentiation period, and in
addition, on day 8 of the differentiation, myotubes were incubated
at 37uC and 5% CO2 with MitoTrackerHRed FM (100 nM) for
15 min to stain mitochondria and Hoechst 33258 (2.5 mg/mL) for
15 min to stain nuclei and washed with PBS in between.
Automated image acquisition was performed in culture medium
without phenol red with an Olympus ScanˆR platform (Olympus
IX81 inverted fluorescence microscope) equipped with a temper-
ature and CO2-enrichment incubator for long-term live imaging,
as described in Hessvik et al [46]. We used a 20X objective and
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live images were aquired in 25 positions per well and 3 wells per
treatment per donor were examined. The background-subtracted
maximal intensity projection from 7 images taken in z-direction
(1 mm apart) was used for both color channels at each position.
Olympus ScanˆR software was used for automated image analysis,
using edge detection algorithm for object segmentation to quantify
the number of nuclei and mitochondrial content(total intensity of
MitoTrackerHRed) per image. After gating out aggregates and
dead cells the results were determined from about 386 images per
treatment (average of 3964 nuclei per image). After 48 h of
chronic, low-frequency EPS, citrate synthase (CS) activity was
determined spectrophotometrically from cell homogenates pre-
pared from the myotubes according to the supplier’s protocol
(Citrate Synthase Activity Assay Kit, Sigma-AldrichH, St. Louis,
MO). Citrate synthase activity in cell homogenates from myotubes
stimulated for 48 h was compared to activity in homogenates from
unstimulated control myotubes.
RNA isolation and analysis of gene expression by
TaqManH Real-Time RT-PCR
Cells were harvested and total RNA was isolated by Agilent
Total RNA isolation kit according to the supplier’s total RNA
isolation protocol. Total RNA was reverse-transcribed with oligo
primers using a Perkin-Elmer Thermal Cycler 9600 (25uC for
10 min, 37uC for 1 h 20 min, and 85uC for 5 min) and a TaqMan
reverse transcription reagents kit. Two micrograms of total RNA
were added per 20 mL of total TaqMan reaction solution. Real-
time PCR was performed using an ABI PRISMT 7000 Detection
System (Applied Biosystems, Warrington, UK). RNA expression
was determined by SYBRT Green, and primers were designed
using Primer ExpressT (Applied Biosystems, Warrington, UK).
Each target gene was quantified in triplicate and carried out in a
25 mL reaction volume according to the supplier’s protocol. All
assays were run for 40 cycles (95uC for 12 s followed by 60uC for
60 s. The transcription levels were normalized to the housekeeping
control gene 36B4. Another housekeeping control gene tested,
GAPDH, gave similar results as 36B4. Following forward and
reverse primers were used at concentration of 30 mM: 36B4
(acc_no M17885): F:CCATTCTATCATCAACGGGTACAA,
R: AGCAAGTGGGAAGGTGTAATCC; GAPDH (acc_no
NM002046): F: TGCACCACCAACTGCTTAGC, R: GGC-
ATGGACTGTGGTCATGAG; CPT1b (acc_no : L39211): F:
GAGGCCTCAATGACCAGAATGT, R: GTGGACTCGCTG-
GTACAGGAA; cytochrome C (acc_no NM001916): F: CT-
GCCAACAACGGAGCATT, R: CGTGAGCAGGGAGAAGA-
CGTA; PGC-1a (acc.no NM013261.3): AAAGGATGCGC-
TCTCGTTCA, R: TCTACTGCCTGGAGACCTTGATC; IL-
6 (acc_no NM000600): F: CGGGAACGAAAGAGAAGCTC-
TAT, R: AGGCGCTTGTGGAGAAGGA; PDK4 (acc_no
BC040239): F: TTTCCAGACCAACCAATTCACA, R: TGC-
CCGCATTGCATTCTTA; GLUT1 (acc_no K03195): F: CA-
GCAGCCCTAAGGATCTTCTCA, R: CCGGCTCGGCT-
GACATC; GLUT4 (acc_no M20747): F: ACCCTGGTC-
CTTGCTGTGTT, R: ACCCCAATGTTGTACCCAAACT;
MHCI (acc_no NM005963) : F: CCAGACTGTGTCTGCTC-
TCTTCAG, R: CAGGACAAGCTCATGCTCC-AT; MHCIIa
(acc_no NM017534): F: AAGGTCGGCAATGAGTATGTCA,
R: CAACCATCCACAGGAACATCTTC.
Data presentation and statistics
Statistical analysis of the overall effects of acute, high-frequency
EPS on the contents of ATP, PCr and lactate was performed using
linear mixed models (LMM) (SPSS version 17, SPSS Inc.,
Chicago, IL). In experiments where effects of 24 h and 48 h
EPS were compared to unstimulated control cells, data were
analyzed using non-parametric Kruskal-Wallis test, while in
experiments where two groups were compared (EPS-treatment
versus unstimulated control cells), non-parametric Wilcoxon
matched pair tests were performed (GraphPad Prism 5.0 for
Windows, GraphPad Software Inc., San Diego, CA). All values in
figures are presented as means6SEM, with n representing the
number of experiments performed, each experiment were
performed with cells from separate (different) donors, with
triplicate samples in each experiment. Statistical significance was
set at P,0.05. In most experiments, results are presented
normalized to unstimulated control cells, and the absolute values
of unstimulated control cells are stated in the figure text.
Results
Effects of acute, high-frequency EPS on deoxyglucose
uptake, cell contents of ATP, PCr and lactate
in cultured myotubes
To verify that electrical stimulation of cultured human
myotubes leads to expected metabolic changes, the myotubes
were exposed to acute, high-frequency EPS, and deoxyglucose
uptake and cellular contents of ATP, PCr and lactate were
examined. Frequency-dependence of deoxyglucose uptake dur-
ing EPS is showed in Figure 1A. Acute, high-frequency EPS
increased deoxyglucose uptake in cultured myotubes (Fig. 1B).
This uptake was specific, since it was inhibited by cytochalasin B
(20 mM) (data not shown). In addition, the amount of
deoxyglucose taken up by electrically stimulated myotubes
correlated positively with the duration of stimulation. Cell
contents of ATP and PCr in electrically stimulated myotubes
were compared to unstimulated control cells incubated for the
same period of time. In response to 5–60 min of electrical
stimulation, the contents of both ATP and PCr decreased
significantly (P= 0.001 and P= 0.007, respectively), while the
amount of lactate significantly increased (P= 0.03) (Figure 1C,
overall effect, linear mixed model, SPSS). Together, these
findings indicated that the cells were contracting and consuming
energy, and that they responded to acute EPS in a similar way as
a single bout of exercise in vivo.
Effects of chronic, low-frequency EPS on glucose
metabolism in cultured human skeletal muscle cells
We were further interested in whether the effects of chronic,
low-frequency EPS on cultured human skeletal cells could mimic
the effects of regular exercise in vivo. A movie showing contractions
of cultured skeletal muscle cells under EPS is attached as Video S1.
Deoxyglucose uptake was significantly increased (P= 0.004) in
cultured myotubes after both 24 and 48 h of chronic, low-
frequency EPS by 96% and 145%, respectively, compared to
unstimulated control cells. The insulin effect was unaffected by
EPS (data not shown). As with acute, high-frequency EPS, the
observed increase in deoxyglucose uptake after chronic, low-
frequency EPS was specific, since it was inhibited by cytochalasin
B (20 mM) (data not shown). Glucose oxidation, measured as the
amount of CO2 produced, was also significantly increased
(P= 0.008) after 48 h of chronic, low-frequency EPS compared
to unstimulated control (Fig. 2A).
Effects of chronic, low-frequency EPS on fatty acid
metabolism in cultured myotubes
A known effect of exercise is to increase oxidative capacity of the
cells, resulting in increased oxidation of both glucose and fatty
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acids. We examined the effect of chronic, low-frequency EPS on
oleic acid metabolism by measuring uptake, and production of
acid soluble metabolites (ASMs) and CO2. Complete oleic acid
oxidation, measured as the amount of produced CO2, was
significantly increased (P= 0.04) after 48 h of EPS by 35%
compared to control cells (Fig. 2B). Uptake of oleic acid was
unaffected by EPS compared to unstimulated control cells
(Fig. 2B). b-oxidation, measured as the amount of ASMs, also
remained unchanged after EPS compared to unstimulated control
cells (Fig. 2B).
Effects of chronic, low-frequency EPS on mitochondrial
content and citrate synthase activity
To support the results obtained in the metabolic experiments
with glucose and oleic acid, we investigated effects of chronic, low-
frequency stimulation for 48 h on mitochondrial content in
cultured myotubes. Representative images are presented for
control, unstimulated myotubes in figure 3A (left), and for
electrically stimulated myotubes in figure 3A (right). Total intensity
of MitoTrackerHRed FM per nucleus was significantly increased
(2.2-fold, Fig. 3B, P= 0.03), and the citrate synthase activity
tended to increase (P=0.1, Fig. 3C) in EPS-treated cells compared
to unstimulated control cells.
Effects of chronic, low-frequency EPS on gene
and protein expression in cultured myotubes
The observed functional changes in fatty acid and glucose
metabolism were accompanied by a range of changes in mRNA
expressions (Fig. 4). mRNA expression level of pyruvate
dehydrogenase complex kinase 4 (PDK4) was significantly
increased (P= 0.04) after 24 h of EPS (Fig. 4). mRNA expression
levels of following genes also tended to increase: CPT1b (P= 0.06),
Figure 1. Frequency-dependence of deoxyglucose uptake (A)
effects of acute, high-frequency EPS on deoxyglucose uptake
(B) and cell contents of ATP, PCr and lactate (C). A: Frequency-
dependence of deoxyglucose uptake: Eight days after the onset of
differentiation, cultured myotubes were incubated in serum-free DMEM
(5.5 mmol/L glucose) for 1 h in a 5% CO2 incubator at 37uC, before
addition of [3H]deoxyglucose (1 vmCi/mL). Electrical pulse stimulation
(30 V, pulse trains of 200 ms) was applied to the cells using frequencies
of either 2, 5 or 10 Hz for the first 15 min of the deoxyglucose uptake
period (60 min). Values are presented as means6SEM of 4 experiments,
normalized to unstimulated control cells (absolute values 56.4–
333.6 nmol/mg). B:Deoxyglucose uptake: Eight days after the onset of
differentiation period, cultured myotubes were incubated in serum-free
DMEM (5.5 mmol/L glucose) for 1 h in a 5% CO2 incubator at 37uC,
before addition of [3H]deoxyglucose (1 mCi/mL). Electrical pulse
stimulation (100 Hz, 30 V, pulse trains of 200 ms given every 5th
second) was applied to the cells the first 5-15-30 min of the
deoxyglucose uptake period or during the whole period (60 min) of
deoxyglucose uptake. Values are presented as means6SEM of 6
experiments, normalized to unstimulated control cells (57.9–92.5 nmol/
mg). C: Cell contents of ATP, phosphocreatine (PCr) and lactate: Eight
days after the onset of differentiation period, the myotubes were
preincubated for 1 h (37uC, 5% CO2) with DMEM and high-frequency
electrical stimulation (100 Hz, 30 V, pulse trains of 200 ms given every
5th second) was applied for 5–60 min. The cells were analyzed for ATP
and PCr levels with luminescence spectrometry, and cell content of
lactate was analyzed with fluorescence spectrometry as described in
Materials and Methods. Values are presented as means6SEM of 3
experiments, normalized to unstimulated control cells (absolute values:
ATP; 42.5–73.9 nmol/mg, PCr; 48.4–169.1 nmol/mg and lactate; 1.9–
87.6 nmol/mg). Overall effect of electrical pulse stimulation on cells was
statistically significant (linear mixed model, SPSS) compared to
unstimulated control cells (P = 0.001 for ATP, P = 0.007 for PCr and
P = 0.03 for lactate).
doi:10.1371/journal.pone.0033203.g001
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Cytochrome c (P= 0.07), PGC-1a (P= 0.2) and IL-6; a myokine
reported to be secreted from contracting skeletal muscles in vivo
[35,36] (P= 0.07) (Fig. 4). GLUT1 and GLUT4 were not affected
by EPS (Fig. 4). The results from immunoblots of phosphorylated
Akt to total Akt ratio, showed no effect of electrical pulse
stimulation (data not shown). Protein expressions of the complexes
in the electron transport chain were unchanged by EPS (data not
shown).
Effects of chronic, low-frequency EPS on the markers
of slow-oxidative (MHCI) and fast glycolytic (MHCIIa)
fiber type
To assess the effect of EPS on fiber type markers in myotubes,
we further investigated expression of genes and proteins
specifically enriched in either type I (slow) fibers (MHCI) or type
IIa (fast) fibers (MHCIIa). Expressions of MHCI and MHCIIa
appeared to increase and decrease, respectively, thus the MHCI/
MHCIIa mRNA ratio tended to increase (P= 0.06) in electrically
stimulated myotubes (Fig. 5A). Protein expression of MHCI was
significantly increased (P= 0.03) by 45% after 24–48 h of EPS
(Fig. 5B, C).
Evaluation of toxic effects of EPS on cultured myotubes
Protein contents of the cells were unaffected by acute, high-
frequency as well as chronic, low-frequency EPS under the
conditions used in the experiments (data not shown). Further,
lactate dehydrogenase content was unchanged in media from
myotubes exposed to chronic, low-frequency EPS for both 24 h
and 48 h compared to unstimulated control cells (data not shown).
Number of nuclei in myotubes after 48 h of chronic, low-
frequency EPS, determined by live imaging of the cells, did not
differ from unstimulated control cells (data not shown). After
staining with trypan blue, a low percentage (less than 1%) was
stained, both in control cells and in electrically stimulated
myotubes, with no difference between the two groups (data not
shown). In conclusion, EPS did not induce toxic effects to cultured
human skeletal muscle cells.
Discussion
Cultured myotubes are a valuable tool for investigation of
metabolic processes in skeletal muscles. In the present study, we
demonstrate how a cell model of human myotubes can be
established as an in vitro model of exercise, which can be used to
study some of the adaptations seen in trained skeletal muscles.
Two different patterns of electrical pulse stimulation (EPS) were
applied: acute, high-frequency EPS (bipolar pulse trains of 200 ms,
100 Hz, given every 5th second, 30 V for 5–60 min) to simulate a
single bout of exercise; and chronic, low-frequency EPS (single,
bipolar pulses of 2 ms, 1 Hz at 30 V for 24 or 48 h) to simulate
regular exercise.
By acutely stimulating cultured myotubes with high-frequency
EPS, glucose uptake and cell lactate content increased, while ATP
and PCr contents decreased. By continuously applying chronic,
low-frequency EPS, we successfully increased oxidative capacity of
the cells by increasing glucose metabolism and complete oleic acid
oxidation. Further, these functional changes in the metabolic
processes were accompanied by doubling of mitochondrial
content, measured as total intensity of MitoTrackerHRed, after
48 h of EPS. Citrate synthase activity tended to increase in EPS-
treated myotubes, although not significantly. Increased mitochon-
Figure 2. Effects of chronic, low-frequency EPS on glucose (A) and oleic acid metabolism (B). Cultured myotubes were electrically
stimulated (1 Hz, 2 ms pulses, 30 V), for the last 24 h or 48 h of the differentiation period. (A) Deoxyglucose uptake: After termination of electrical
stimulation (day 8 of differentiation), uptake of [3H]deoxyglucose (1 mCi/mL) was measured for 1 h as described in Materials and Methods. Values are
presented as means6SEM of 6 experiments. *Significantly different from unstimulated control cells (absolute values 28.0–170.5 nmol/mg protein)
(P = 0.004, non-parametric Kruskall-Wallis test). Glucose oxidation: After termination of electrical stimulation (day 8 of differentiation), the rate of D-
[14C(U)]glucose (2 mCi/mL) oxidation was measured as described in Materials and Methods. Values are presented as means6SEM of 4 experiments.
*Statistically significant compared to unstimulated control cells (absolute values 2.7–28.4 nmol/mg protein) (P = 0.008, non-parametric Kruskall-Wallis
test). (B) Oleic acid metabolism: Eight or nine days after the onset of differentiation, myotubes were exposed to [1-14C]OA (1 mCi/mL) for 2 h, and
CO2, ASMs and cell-associated (CA) radioactivity were measured as described in Materials and Methods. Values are presented as means6SEM of 8
experiments. *Statistically significant vs. unstimulated control myotubes (absolute values 15.0–166.8 nmol/mg protein for CA, 0.6–4.0 nmol/mg
protein for ASMs and 0.2–2.9 nmol/mg protein for CO2) (P = 0.04, non-parametric Kruskall-Wallis test).
doi:10.1371/journal.pone.0033203.g002
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drial content in skeletal muscles after exercise is believed to result
from the cumulative effects of transient increases in mRNA
transcripts encoding mitochondrial proteins after repeated exercise
sessions [3,47]. Temporal sequences of molecular effects that
occur in human muscle when mitochondrial biogenesis is induced
with exercise training were investigated in a study by Perry et al.
[48]. Although CS mRNA increased already after first training
session, increase in the activity of CS was not observed until the
end of the 3rd of the seven performed training sessions. In general,
repeated transient bursts of mRNA were shown to occur in the
early phases of training, before increases in the activities of
mitochondrial proteins, but the time and magnitude of mRNA
and protein responses of different transcriptional and mitochon-
drial proteins also showed considerable variation, depending on
the phase of the exercise they were measured in [48]. Thus, the
lack of significant increase in CS activity in our experiments after
only 48 hours of EPS is in agreement, or at least reflects the
complexity and precise time-dependence of molecular events that
were described to occur in mitochondrial biogenesis during
exercise in human skeletal muscles. At applied conditions, we
did show expected functional changes (lipid oxidation and glucose
metabolism), as well as changes in mRNA and protein expressions
of some factors, but in order to demonstrate other changes, both
on mRNA and protein level, we would perhaps have to use
different patterns and time periods, and with the present model,
this is something that can be done in the future work. The same
inconsistency between citrate synthase activity and MitoTrack-
erHRed intensity has also been reported in a recent work
presenting a novel, exercise-mimicking approach to remodel lipid
metabolism in cultured human myotubes [49]. Interestingly, this
was a cell system like ours, but the exercise-mimicking effects were
induced by a pharmacological activation. Thus, for future studies,
time aspect may be an important factor to be considered when
performing exercise-mimicking studies in cell cultures.
Changes in expression levels of a range of genes were also
observed after chronic EPS. mRNA level of PDK4 was
significantly increased in electrically stimulated cells, while mRNA
levels of Cytochrome c and CPT1b also tended to increase.
Figure 3. Effects of 48 h of chronic, low-frequency EPS on mitochondrial content and citrate synthase activity. Low-frequency EPS was
applied to cultured myotubes for the last 48 h of the eight days differentiation period as described in Materials and Methods. (A) Live imaging of
mitochondria: The cells were stained for nuclei (blue) and mitochondria (red) as described in Materials and Methods. Scale bar is 50 mm. Left:
Unstimulated control myotubes. Right: Myotubes after 48 h of chronic, low-frequency EPS. (B) Mitochondrial content in electrically stimulated
myotubes: Mitochondrial content was measured by live imaging after 48 h of chronic, low-frequency EPS. Values are presented as means6SEM of 6
experiments. *Statistically significant vs. unstimulated control (P = 0.03, non-parametric Wilcoxon matched pair test). (C) Citrate synthase activity
in electrically stimulated myotubes: Enzyme activity was determined spectrophotometrically from cell homogenates prepared from the
myotubes after 48 h of chronic, low-frequency EPS as described in Materials and Methods, and compared to activity in unstimulated control cells.
Values are presented as means6SEM of 5 experiments.
doi:10.1371/journal.pone.0033203.g003
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GLUT1 and GLUT4 did not appear to be affected by EPS.
Moreover, the ratio of the mRNA level of MHCI (a gene marker
of type I, slow oxidative fiber type), to that of MHCIIa (a gene
marker of glycolytic, fast-twitch skeletal muscle fibers) tended to
increase in electrically stimulated myotubes, and this finding was
also supported by increased protein expression of MHCI in EPS-
treated cells. Further, mRNA expression of peroxisome prolif-
erator-activated receptor c coactivator-1a (PGC-1a), a transcrip-
tional cofactor referred to as the master regulator of mitochondrial
function and biogenesis [50]; which is frequently considered as an
important factor in cellular mechanisms evoked by exercise,
tended to increase, although not significantly, as well as mRNA
level of IL-6, an interleukin known to be secreted by skeletal
muscles after exercise in vivo, strengthening the conclusion that our
model of EPS may resemble trained muscle.
The relative contribution of fatty acid oxidation to total fuel
demand is increased in healthy subjects performing moderate-
intensity exercise, and several studies support that exercise reduces
the reliance on carbohydrates as an energy source and increases
fatty acid oxidation [51,52]. The rate of oleic acid oxidation was
significantly increased after 48 h of EPS in our cell culture model,
while the uptake of oleic acid was unchanged. Although exercise
has been shown to increase uptake of fatty acids in humans,
cellular mechanisms of elevated uptake are still not clear, since
inconsistencies exist due to different duration and intensity of
training studies [53]. A key factor facilitating transport of fatty
acids through the carnitine shuttle over the outer mitochondrial
membrane, CPT1b, has been shown to be increased in an in vivo
human training study with moderate-intensity exercise for a
shorter duration (2 months), accompanied by an increase in
mitochondrial fatty acid oxidation rate [54]. Although not
significantly, mRNA expression level of CPT1b tended to increase
in our EPS cell model as well.
Our model of chronic, low-frequency EPS showed both
increased import and oxidative metabolism of glucose, and these
effects are also known from in vivo trained fibers [25,26]. However,
we did not observe any additional effect of insulin and EPS on
glucose uptake, nor was phosphorylation of Akt affected by EPS.
These observations are in agreement with suggestions of an
insulin-independent pathway to enhance glucose uptake [55,56].
In addition, there are proposals that some key metabolic
substances typically triggered by insulin, may also be activated
during muscle contractions in the absence of this hormone [26].
mRNA expression levels of GLUT1 and GLUT4 were unaffected
by EPS. GLUT4 is often deficient in cultured skeletal muscle cells
[57], and in primary human myotubes, basal glucose uptake is
generally mediated by other glucose transporters, such as GLUT1
and GLUT3 [58,59]. Inconsistencies between mRNA levels of
Figure 4. Effects of chronic, low-frequency EPS on gene
expression. Low-frequency EPS was applied to cultured myotubes
for the last 24 h or 48 h of the eight days differentiation period. mRNA
was isolated and expression assessed by real time RT-PCR as described
in Materials and Methods, and values are presented as means6SEM of
3–6 experiments, normalized to levels of housekeeping genes 36B4. The
ranges of the fold changes of the mRNA expression levels in the control
groups normalized to the level of housekeeping gene 36B4 were as
follows: 0.3–1.9 for CPT1b, 0.4–1.3 for cytochrome C, 0.001–0.6 for PGC-
1a, 0.6–1.2 for GLUT1, 0.2–2.6 for GLUT4, 0.7–1.0 for PDK4 and 0.1–1.1
for IL-6. *Statistically significant vs. unstimulated control cells (P = 0.04,
non-parametric Kruskall-Wallis test).
doi:10.1371/journal.pone.0033203.g004
Figure 5. Effects of chronic, low-frequency EPS on markers of slow-oxidative (MHCI) and fast-glycolytic (MHCIIa)muscle fiber types.
Low-frequency EPS was applied to cultured myotubes for the last 24 h or 48 h of the eight days differentiation period as described in Materials and
Methods before the cells were harvested. (A) MHCI/MHCIIa mRNA ratio: mRNA was isolated from cultured myotubes after the EPS treatment.
Expression was assessed by RT-PCR as described in Materials and Methods, and values are presented as means6SEM of 4 experiments, normalized to
levels of housekeeping genes 36B4. (B) (C) Immunoblot analysis of MHCI after 24–48 h of EPS: Aliquots of 40 mg cell protein from total cell
lysates prepared in Laemmli buffer were electrophoretically separated on NuPAGEH 4–12% (w/v) Bis-Tris Gel, followed by immunoblotting with
specific antibody for slow-oxidative MHCI. (B) One representative immunoblot. (C) Densitometric analysis of immunoblots, values are presented as
means6SEM of 6 experiments. *Statistically significant vs. unstimulated control cells (P = 0.03, non-parametric Wilcoxon matched pair test).
doi:10.1371/journal.pone.0033203.g005
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GLUTs and functional data have previously been reported in
cultured human skeletal muscle cells [60,61]. On the other hand,
PDK4, an inhibitor of pyruvate dehydrogenase complex, which is
an important factor in switching oxidation towards fatty acids [62],
was significantly increased in EPS-treated cells, indicating a
possible switch in the fuel preference of the myotubes. When
grown in culture, satellite cells mature to myotubes that generally
display the characteristics of glycolytic type II muscle fibers [41],
and are characterized by low mitochondrial oxidative capacity
[63,64], with higher fuel preference for carbohydrates over lipids
[65]. This could be due to lack of proliferation of mitochondria in
vitro in the absence of appropriate environmental signals, such as
contractions. Thus, approaches that increase mitochondrial
oxidative potential of human myotubes are highly relevant with
respect to studies on cellular energy metabolism.
Even though it is difficult to directly compare effects of in vivo
exercise to the observed effects in our model of EPS in cultured
human myotubes, several of our observations display important
aspects of the in vivo effects of exercise. In summary, by applying
our model of chronic continuous, low-frequency EPS, we observed
important functional changes in cell culture: improved lipid
oxidation and glucose metabolism, which are known effects of
exercise in vivo. Further, we also demonstrated a possible fiber-type
switch, measured by increased protein expression of MHCI in
EPS-treated cells. To our knowledge, such changes have not
previously been reported in human cell cultures. Thus, we believe
that our model of EPS in cultured human skeletal muscle cells
represents a unique, physiologically relevant ex vivo model, which
can be used to further study interrelationship between exercise-
induced cellular mechanisms and underlying signalling pathways
under controlled conditions. Particularly, the present model might
be of great interest in clarifying the potential of contractions on
energy metabolism in skeletal muscle cells obtained from different
groups of individuals (obese, glucose intolerant, athletes etc.).
Currently, contraction-induced effects on energy metabolism in
human skeletal muscle cells originating from extremely obese
individuals with or without type 2 diabetes are being investigated.
Supporting Information
Video S1 A film showing contractions of cultured
human skeletal muscle cells exposed to chronic, low-
frequency EPS. Cultured human skeletal muscle cells were
exposed to chronic, low-frequency EPS (single, bipolar pulses of
2 ms, with 30 V and 1 Hz continuously for the last 24 or 48 h of
differentiation period). The observed contractions were synchro-
nous with the electrical pulses.
(M4V)
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Unfortunately there was a mistake in Figure 5A. The primer used for mRNA expression was actually 
MYH1 which regulates expression of MHC type IIx muscle fibers and not MHC type I as stated in the 
figure. However, we have repeated the experiment with the correct primer MYH7 (acc_no 
NM000257.2, F: CTCTGCACAGGGAAAATCTGAA, R: CCCCTGGAGACTTTGTCTCATT), and the new Figure 
5 is shown here. This makes no difference to the conclusions of the paper. Chronic low frequent 
electrical pulse stimulation for 48 h increased expression of slow muscle fibers assessed by Western 
blotting, but there were no significant change in mRNA expression observed at the same time, 
neither was the MHCI/MHCIIa mRNA ratio significantly increased (p=0.125, non-parametric Wilcoxon 
matched pair test, n=4). 
Figure 5 
Effects of chronic, low-frequency EPS on markers of slow-oxidative (MHCI) and fast-glycolytic 
(MHCIIa) muscle fiber types. Low-frequency EPS was applied to cultured myotubes for the last 24 h 
or 48 h of the eight days differentiation period as described in Materials and Methods before the 
cells were harvested. (A) MHCI/MHCIIa mRNA ratio: mRNA was isolated from cultured myotubes 
after the EPS treatment. Expression was assessed by RT-PCR as described in Materials and Methods, 
and values are presented as means ± SEM of 4 experiments, normalized to levels of housekeeping 
genes 36B4. (B) (C) Immunoblot analysis of MHCI after 24–48 h of EPS: Aliquots of 40 μg cell protein 
from total cell lysates prepared in Laemmli buffer were electrophoretically separated on NuPAGE® 4–
12% (w/v) Bis-Tris Gel, followed by immunoblotting with specific antibody for slow-oxidative MHCI. 
(B) One representative immunoblot. (C) Densitometric analysis of immunoblots, values are presented 
as means±SEM of 6 experiments. *Statistically significant vs. unstimulated control cells (P = 0.03, 
non-parametric Wilcoxon matched pair test). 
 
